salicylic acid has been researched along with Cicatrization in 356 studies
Scalp: The outer covering of the calvaria. It is composed of several layers: SKIN; subcutaneous connective tissue; the occipitofrontal muscle which includes the tendinous galea aponeurotica; loose connective tissue; and the pericranium (the PERIOSTEUM of the SKULL).
Cicatrization: The formation of fibrous tissue in the place of normal tissue during the process of WOUND HEALING. It includes scar tissue formation occurring in healing internal organs as well as in the skin after surface injuries.
Excerpt | Relevance | Reference |
---|---|---|
"Many clinicians have used glycolic acid (GA) peels for facial acne, scarring, and hyperpigmentation, mainly in lighter skin types." | 7.75 | Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. ( Garg, VK; Sarkar, R; Sinha, S, 2009) |
"Many clinicians have used glycolic acid (GA) peels for facial acne, scarring, and hyperpigmentation, mainly in lighter skin types." | 3.75 | Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study. ( Garg, VK; Sarkar, R; Sinha, S, 2009) |
"Multiple approaches are used to treat acne scars, but some are expensive, ineffective, and cause complications." | 3.11 | Combination treatment with 30% salicylic acid and fractional CO ( Chen, J; Chen, JY; Chen, YM; Liu, L; Pu, YH; Shao, XY; Zhang, LZ; Zhang, YJ, 2022) |
"When untreated, scarring alopecia develops." | 3.01 | EROSIVE PUSTULAR DERMATOSIS OF THE SCALP (EPDS) - A CASE SERIES AND SHORT REVIEW. ( Wollina, U, 2023) |
"When a cicatricial alopecia is suspected, scalp biopsy is recommended." | 2.82 | Treatment of Alopecia in Children. ( Gold, M; Goldust, M; Grabbe, S; Mishra, P; Patil, A; Rudnicka, L; Sinclair, R, 2022) |
"At Month 12, hyperplastic scars at these donor sites of cicatricial skin were assessed through Vancouver Scar Assessment Table, scar itch assessment and scar proliferation rate." | 2.78 | [Clinical study of repairing donor site of thickness from cicatricial skin with auto-scalp grafting]. ( Cai, JD; Cai, JH; Chai, JK; Li, DJ; Shen, CA; Tuo, XY; Wang, SJ; Zhang, L; Zhu, H, 2013) |
"We evaluate a new technique of treating scalp lacerations, the hair apposition technique (HAT)." | 2.70 | A randomized controlled trial comparing the hair apposition technique with tissue glue to standard suturing in scalp lacerations (HAT study). ( Hock, MO; Lim, SH; Ooi, SB; Saw, SM, 2002) |
"The incidence of inflammation, suppuration and hypertrophic scarring was recorded, along with the timing of spontaneous suture disappearance." | 2.69 | Outcomes of irradiated polyglactin 910 Vicryl Rapide fast-absorbing suture in oral and scalp wounds. ( Aderriotis, D; Sàndor, GK, 1999) |
"Twelve patients with post-burn contracture were treated using artificial dermis combined with thin split-skin grafting during the period January 1994 to April 1996." | 2.68 | Reconstruction of burn deformity using artificial dermis combined with thin split-skin grafting. ( Negishi, N; Nozaki, M; Sasaki, K; Soejima, K; Takeuchi, M, 1997) |
"Analyzing other scarring diseases (lichen planopilaris, fibrotic kidney disease and scleroderma) may help to clarify the mechanism of scarring in CCCA." | 2.66 | A proposed mechanism for central centrifugal cicatricial alopecia. ( Alexander, T; Beamer, V; McMichael, A; Subash, J, 2020) |
"In addition, the scar width was 60 to 76 percent larger in the Dexon group 3 months postoperatively." | 2.66 | Absorbable versus nonabsorbable sutures to prevent postoperative stretching of wound area. ( Nordström, RE; Nordström, RM, 1986) |
"diffuse and scarring vs." | 2.53 | Diagnosis and management of hair loss in children. ( Castelo-Soccio, L, 2016) |
"With regards to non-scarring alopecia, there were eight horizontal and eight vertical section studies." | 2.53 | Diagnostic value of horizontal versus vertical sections for scarring and non-scarring alopecia: a systematic review and meta-analysis. ( Du, X; Fan, W; Li, Z; Song, C; Tang, S; Xu, W; Zhou, X, 2016) |
"Folliculitis keloidalis is a cicatricial alopecia with a mixed inflammatory infiltrate." | 2.52 | Primary scarring alopecias. ( Ioannides, D; Rigopoulos, D; Stamatios, G, 2015) |
"Hair loss is commonly seen in autoimmune diseases." | 2.50 | Hair loss in autoimmune systemic diseases. ( Cozzani, E; Parodi, A, 2014) |
"Keloid scarring is more prevalent in individuals of African, Asian, and Hispanic descent." | 2.50 | Follicular and scarring disorders in skin of color: presentation and management. ( Kundu, RV; Madu, P, 2014) |
"The relationship between nonscarring scalp alopecia in women and iron deficiency continues to be a subject of debate." | 2.46 | Iron deficiency and diffuse nonscarring scalp alopecia in women: more pieces to the puzzle. ( Donovan, JC; Hordinsky, MK; St Pierre, SA; Vercellotti, GM, 2010) |
"As is well known, scars are the indelible ransom of any surgical procedure and the major obstacle confronting patients and surgeons from an aesthetic standpoint." | 2.44 | Minimal scars for scalp surgery. ( Frechet, P, 2007) |
"A requirement for developing successful treatments for postacne scarring is a greater understanding of its pathogenesis, variability among afflicted individuals, and the inflammatory mediators and immunology of the scarring process." | 2.44 | The management of postacne scarring. ( Baron, JA; Goodman, GJ, 2007) |
"Cicatricial or scarring alopecia represents permanent destruction of the hair follicle, histopathologically showing a decreased number of follicular units leaving streamers of fibrosis or hyalinization of surrounding collagen." | 2.44 | Cicatricial alopecia secondary to radiation therapy: case report and review of the literature. ( Griffin, T; Severs, GA; Werner-Wasik, M, 2008) |
"Although single-scar techniques have been published and are used by approximately half of all surgeons, this approach is not as common as one might suspect." | 2.42 | Intricacies of the single-scar technique for donor harvesting in hair transplantation surgery. ( Brandy, DA, 2004) |
"Unsightly donor scars and fibrosis are still not only with us, but are possibly even more pervasive than ever." | 2.41 | Hair transplantation: management of donor area. ( Seery, GE, 2002) |
"Primary and secondary scarring alopecia are differentiated: While the former is due to preferential destruction of the follicle, the latter results from events outside the follicle, which eventually impinge upon and eradicate the follicle." | 2.40 | [Cicatricial alopecias: diagnosis and therapy]. ( Trüeb, RM, 1997) |
"The development of malignancy in burn scars is a well known entity." | 2.40 | Sarcoma developing in a burn scar: case report and review of the literature. ( Apaydin, EI; Can, Z; Kuzu, I; Riza, A; Yilmaz, S, 1998) |
"A 23-year-old man with frontal hair loss underwent follicular unit strip surgery." | 1.91 | A Scalp Scar-Reducing Procedure for the Hair Transplant Donor Area Using a Columnar Trichophytic Suture: A Case Report. ( Kim, J; Kim, T; Park, G; Park, J, 2023) |
"Sarcoidosis is an idiopathic multisystem inflammatory disease that can affect virtually any part of the body." | 1.91 | Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series. ( Hosler, GA; Khalid, I; Ogwumike, E; Sode, T, 2023) |
"None of the cases had diagnosis of type 2 diabetes mellitus, but 17." | 1.91 | Central centrifugal cicatricial alopecia in males. ( Ayoade, KO; Jackson, TK; Ogunleye, T; Seykora, JT; Sow, Y; Taylor, SC, 2023) |
"To evaluate the safety and efficacy of FUE when combined with an expanded scalp flap for facial organ reconstruction." | 1.91 | Hair follicle extraction combined with an expanded scalp flap for facial organ reconstruction. ( Fan, Z; Gan, Y; Hu, Z; Le, D; Liu, B; Mao, X; Miao, Y; Qu, Q; Sun, P; Zhang, J, 2023) |
"However, this approach leaves long scars that in numerous patients, it can cause extensive surrounding alopecia and sensory skin deficits." | 1.72 | A new aesthetic pretrichial approach for upper third-facial fractures and pathologies: The "Crown incision". ( De Riu, G; Massarelli, O; Vaira, LA, 2022) |
" In this study, we present an alternative technique to reconstruct the aesthetic units using an expanded scalp flap combined with laser hair removal." | 1.72 | Expanded scalp flap combined with laser hair removal to reconstruct facial defects around the hairline. ( Chu, F; Ding, J; Liu, S; Ma, X; Tang, Y; Yu, Z, 2022) |
" This article introduces an approach to reconstruct total facial injuries with a prefabricated expanded thoracic flap combined with an expanded scalp flap (called combined flaps), which not only solves the limitations of blood supply and expanded volume but also reduces patchwork scars." | 1.62 | Prefabricated Expanded Flap Combined With Expanded Scalp Flap for Total Face Resurfacing. ( Char, S; Liu, Y; Shi, Y; Sun, H; Tan, X; Wang, X; Yang, C; Yao, J; Yao, P, 2021) |
"Burn scar and alopecia on hair-bearing areas can severely affect the social life of patients." | 1.62 | Hair Transplantation in Burn Scar Alopecia After Combined Non-Ablative Fractional Laser and Microfat Graft Treatment. ( Agaoglu, E; Agaoglu, G; Erol, O; Karademir, S; Özer, F, 2021) |
"All patients had no obvious scar at the donor sites." | 1.56 | Clinical outcomes and technical tips for eyebrow restoration using single-follicular-unit hair transplantation: A case series review. ( Jiang, W; Wang, B; Wang, M, 2020) |
"All cases resembled deep-reaching scars with almost complete loss of all adnexal structures." | 1.56 | Aplasia cutis congenita of the scalp: Histopathologic features and clinicopathologic correlation in a case series. ( Bösmüller, H; Gassenmaier, M; Metzler, G, 2020) |
"Surgical scar length is a common concern among patients undergoing Mohs micrographic surgery (MMS)." | 1.51 | A Predictive Model for Primary Closure Lengths in Mohs Surgery Based on Skin Cancer Type, Dimensions, and Location. ( Blechman, AB; Russell, MA; Theroux, ZA, 2019) |
"Patients with androgenetic alopecia (AGA) and alopecia areata (AA), and scarring alopecia, in particular frontal fibrosing alopecia (FFA) were recruited and imaged from July 2016 to July 2017." | 1.51 | Feature characterization of scarring and non-scarring types of alopecia by multiphoton microscopy. ( Atanaskova Mesinkovska, N; Balu, M; Koenig, K; Lentsch, G; Lin, J; Saknite, I; Tromberg, BJ; Valdebran, M; Williams, JN, 2019) |
"Only burn scars caused post-ulceration periods of more than 24 months (7/19)." | 1.51 | A review of 31 cases of Marjolin's ulcer on scalp: Is it necessary to preventively remove the scar? ( Cen, Y; Chen, Z; Deng, K; Gao, Y; Lin, Y; Liu, R; Xiao, H; Xu, X, 2019) |
"To characterize scar formation and hair growth in nonhealing ulcers after transplantation." | 1.51 | Distinct Patterns of Hair Graft Survival After Transplantation Into 2 Nonhealing Ulcers: Is Location Everything? ( Alam, M; Cooley, J; Izeta, A; Jimenez, F; Martínez-Martín, MS; Paus, R; Plotczyk, M, 2019) |
"Of note, patchy primary scarring alopecia (SA) needs to be clearly distinguished from AA as SA can leave permanent hair loss." | 1.51 | Use of trichoscopy for the diagnosis of alopecia areata coexisting with primary scarring alopecia in a female hair loss patient. ( Fukuyama, M; Ohyama, M, 2019) |
"Indication included burn scar (n=14) and congenital nevus (n=5)." | 1.51 | Choosing the right rectangular expander and maximising the benefits from expanded tissue. ( Aksam, E; Durgun, M, 2019) |
"In follicular scars, EVG demonstrated central attenuation and loss of the elastic network with peripheral clumping and recoil of elastic fibers." | 1.48 | Elastic Staining in Differentiating Between Follicular Streamers and Follicular Scars in Horizontal Scalp Biopsy Sections. ( Gerami, P; Guitart, J; Tan, T; Yazdan, P, 2018) |
"Low grade glioma (LGG) is a very common primary brain neoplasm with a very good prognosis and the median survival of patients is approximately 8 years." | 1.48 | Cutaneous Metastases of the Glioma. ( Chang, H; Ding, Y; Li, B; Lin, Y; Wang, P; Wang, Q, 2018) |
"The pattern of hair loss was more likely to be unifocal-ragged border in CCCA and DLE, multifocal-interconnected in LPP and FD, and multifocal-separated in DC." | 1.48 | Primary scarring alopecia: A retrospective study of 89 patients in Taiwan. ( Cheng, AY; Chu, CB; Hsu, CK; Lee, CN; Lee, JY; Liu, CH; Su, HJ; Yang, CC, 2018) |
"One patient had a hypertrophic scar and no hair transfers to the recipient areas were observed." | 1.48 | Scalp as a donor site in children: Is it really the best option? ( Adams, S; Rode, H; van Niekerk, G, 2018) |
"Sarcoidosis is a granulomatous condition that has a highly variable presentation." | 1.48 | Scalp Sarcoidosis Presenting as Cicatricial Alopecia. ( Cook, C; Demaree, E; Powers, J; Prohaska, J, 2018) |
"In stage 2, scarring tissues were excised and the expanded hair-bearing flaps were advanced to the defect." | 1.48 | Staged reconstructive treatment for extensive irregular cicatricial alopecia after burn. ( Cheng, H; Jia, M; Li, J; Shen, H; Sun, Z; Tang, L; Tang, S; Wu, X; Zhang, J; Zhou, J, 2018) |
"One patient had hair loss of the upper cutaneous lip." | 1.46 | Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases. ( Camilleri, MJ; Chaudhry, HM; Tolkachjov, SN; Torgerson, RR, 2017) |
"The seaming scar between the deltopectoral flap and scalp flap in the temple region formed the new hairline." | 1.46 | Reconstruction of Large Postburn Facial-Scalp Scars by Expanded Pedicled Deltopectoral Flap and Random Scalp Flap: Technique Improvements to Enlarge the Reconstructive Territory. ( Li, W; Li, Y; Liu, C; Lu, K; Ma, X; Peng, P; Song, B; Su, Y; Xia, W; Yi, C, 2017) |
"Cutaneous sarcoidosis is not an uncommon disorder, and the skin can be the sole manifestation in about 10% of patients." | 1.46 | Atrophic and Annular Scarring Alopecia of the Scalp as a Finding in Underlying Systemic Sarcoidosis. ( Didona, D; Donati, M; Donati, P; Panetta, C; Paolino, G, 2017) |
"To investigate the feasibility and therapeutic effect of frontal and scalp expanded skin flap combined with laser hair removal for children congenital facial giant nevi." | 1.46 | [Frontal and scalp expanded skin flap combined with laser hair removal for children congenital facial giant nevi]. ( Chen, C; Li, B; Li, W; Sun, Z, 2017) |
"Several reported cases have described scarring alopecia of the scalp, which is the area of skin most commonly affected by sarcoidosis." | 1.43 | Sarcoidosis presenting as non-scarring non-scalp alopecia. ( Dan, L; Relic, J, 2016) |
"Neither scar nor alopecia was found in the skin-harvesting region, and hairs grew well." | 1.43 | [Scalp surface skin grafts in reconstruction of external auditory meatus in congenital aural atresia]. ( Huang, QH; Jiang, HL; Liang, MJ; Liu, Y; Si, Y; Xu, G; Zhang, ZG, 2016) |
"The donor-site scar was larvaceous and the function was good." | 1.43 | Free perforating branch flap for primary repairing the huge soft-tissue defects on the scalp and face. ( Chu, YJ; Sun, JW; Wang, HY; Wang, K; Wang, MG; Wei, XP; Yu, G, 2016) |
"Therefore, scar widening and hair loss after craniotomy, which sometimes occurs in this disease, are serious problems for patients." | 1.42 | Zigzag skin incision effectively camouflages the scar and alopecia for moyamoya disease: technical note. ( Kato, A; Kubota, H; Sanada, Y; Yabuuchi, T; Yoshioka, H, 2015) |
"To investigate the therapeutic effect of scalp expanded flap combined with JPL hair removal for large area scar on forehead." | 1.42 | [Scalp expanded flap combined with IPL hair removal for large area scar on forehead]. ( Hongwei, Y; Hua, L; Hui, G; Li, C; Li, Z; Peng, W; Xia, Y, 2015) |
"Subjective scar evaluation of the donor sites was performed using the Patient Scar Assessment Scale (PASA)." | 1.40 | Comparison of scalp and abdomen as split-thickness skin graft donor sites for aural stenosis repair. ( Du, Q; Zhang, T, 2014) |
"Occipital scars from donor strip harvesting during hair transplantation are an important cosmetic concern." | 1.40 | Measuring occipital scalp laxity before donor strip harvesting in hair transplantation. ( Chang, CH; Chang, SL; Gold, MH; Hu, S; Huang, YL; Lee, MC, 2014) |
"Defect diameters and resultant scar lengths were recorded." | 1.39 | Versatility of the pinwheel flap to reconstruct circular defects in the temporal and scalp region. ( Eroglu, L; Simsek, T, 2013) |
"Alopecia is the fifth most common dermatologic diagnosis in African-American patients." | 1.39 | Prospective histologic examinations in patients who practice traumatic hairstyling. ( Mehregan, DM; Uhlenhake, EE, 2013) |
"The causes of scar resulting to hair loss were burns, operation, and trauma." | 1.39 | Hair follicle transplantation on scar tissue. ( Hoon Koh, S; Jung, S; Oh, SJ, 2013) |
"This leaves a visible scar that may not be cosmetically acceptable." | 1.39 | Subcutaneoscopic excision of external angular dermoid cyst in children without conspicuous scarring. ( Acharya, H; Agarwal, P; Agrawal, V; Sekhon, V; Sharma, D, 2013) |
"The pathogenesis of scarring alopecia in African American women remains poorly understood." | 1.39 | Transversely sectioned biopsies in the diagnosis of end-stage traction alopecia. ( Donovan, JC; Mirmirani, P, 2013) |
"FFA is an increasingly common form of scarring hair loss, but the origin remains unknown." | 1.39 | Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University. ( Bazakas, A; Ladizinski, B; Olsen, EA; Selim, MA, 2013) |
"Another common problem is the scar enlargement." | 1.38 | Long-term results in scalp tissue expansion in children. ( Calibre, C; Duquennoy-Martinot, V; Herbaux, B; Maillet-Declerck, M, 2012) |
"The results showed minimal scarring and hair regrowth in what could have been large defects requiring complex reconstruction." | 1.36 | The use of the flexible scalpel for minimally invasive and minimally scarring surgery: a case series of four patients with large scalp tumors. ( Firoz, BF; Friedman, PM; Goldberg, LH; Katz, T; Kimyai-Asadi, A, 2010) |
"All had frontotemporal recession with scarring." | 1.35 | Frontal fibrosing alopecia: clinical presentations and prognosis. ( Messenger, AG; Tan, KT, 2009) |
"In a specialized hair loss clinic, a group of patients was identified with focal or complete hair loss at the scalp periphery, with a normal scalp surface." | 1.35 | Cicatricial marginal alopecia: is it all traction? ( Goldberg, LJ, 2009) |
"Tinea capitis is the most common dermatophyte infection in children." | 1.35 | Tinea capitis mimicking cicatricial alopecia: what host and dermatophyte factors lead to this unusual clinical presentation? ( Chamlin, S; Frieden, IJ; Mirmirani, P; Price, VH; Willey, A, 2009) |
"When the hemangiomas were stratified into "large" and "small" hemangiomas, the median percentage reduction in the areas were 84." | 1.35 | Purse-string closure of hemangiomas: early results of a follow-up study. ( Rohde, CH; Wu, JK, 2009) |
"Cicatricial or scarring alopecia results in the destruction of hair follicles and is a significant cosmetic concern in African-American women." | 1.35 | Scarring alopecia: clinical and pathologic study of 54 African-American women. ( Borovicka, JH; Mehregan, DR; Prince, C; Thomas, L, 2009) |
"Although non-scarring diffuse hair loss has been frequently observed in systemic lupus erythematosus (SLE) patients, the pattern of hair loss with regard to its frequency in SLE has been rarely studied." | 1.34 | Cross-sectional study of hair loss patterns in 122 Korean systemic lupus erythematosus patients: a frequent finding of non-scarring patch alopecia. ( Kim, SJ; Kim, SY; Lee, JB; Lee, JW; Lee, SC; Lee, SS; Won, YH; Yoon, HJ; Yun, SJ, 2007) |
"These lesions resolved gradually with scar formation." | 1.33 | A case of lupus erythematosus profundus with unusual manifestations. ( Alpsoy, E; Bacanli, A; Ciftcioglu, MA; Uzun, S, 2005) |
"The postburn scars were removed, and the wounds were covered by superficial cervical artery island skin flaps." | 1.33 | [The use of superficial cervical artery island skin flaps in the repair of the maxillofacial and cervical scar]. ( Chen, SJ; Han, WJ; Wang, B; Wang, DL; Wang, YM; Wei, ZR, 2005) |
"Aplasia cutis congenita is a special condition, with local vascular abnormalities: local flaps are prohibited." | 1.33 | [Scalp surgery in children: principles and therapeutic aspects]. ( Buis, J; Delbecque, M; Franchi, G; Picard, A; Sergent, B; Vazquez, MP, 2005) |
"Female pattern hair loss (FPHL) is a common hair disorder of the central scalp." | 1.33 | Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective. ( Olsen, EA, 2005) |
"Sclerodermatous skin changes and scarring alopecia are described in up to 20% of patients." | 1.33 | Large, nonhealing scalp ulcer associated with scarring alopecia and sclerodermatous change in a patient with porphyria cutanea tarda. ( Bergamo, BM; Inglese, MJ, 2005) |
"None of the other patients had any scarring; they were completely healed by day 15." | 1.33 | The scalp is an advantageous donor site for thin-skin grafts: a report on 945 harvested samples. ( Chaouat, M; Mimoun, M; Picovski, D; Serroussi, D; Smarrito, S, 2006) |
"Most patients were men treated for androgenic alopecia." | 1.32 | Algorithm of hair restoration surgery in children. ( Kolasiñski, J; Kolenda, M, 2003) |
"Neck scar contractures were released in all cases, and good results were obtained not only functionally but also aesthetically." | 1.32 | Clinical and basic research on occipito-cervico-dorsal flaps: including a study of the anatomical territories of dorsal trunk vessels. ( Gao, JH; Hyakusoku, H; Murakami, M; Ogawa, R, 2004) |
"Wide unsightly scars, stretch-atrophied hypesthetic, poorly vascularized tissues and distorted hair patterns are still commonly seen and appear to be largely refractory to remedial surgery." | 1.31 | Surgical anatomy of the scalp. ( Seery, GE, 2002) |
"The authors report a case of aplasia cutis congenita of the scalp associated with bilateral coronal synostosis." | 1.31 | Surgical treatment of aplasia cutis congenita of the scalp associated with bilateral coronal synostosis. ( Arai, H; Ichida, M; Inoue, M; Komuro, Y; Miyajima, M; Sato, K; Seno, H; Yanai, A, 2002) |
"Hair loss from the flap was rare." | 1.31 | New treatment of a visible linear scar in the scalp: multiple hair-bearing flap technique. ( Sawada, Y; Urushidate, S; Watanabe, Y; Yamashita, K; Yokoi, K; Yotsuyanagi, T, 2002) |
"Accurate data for the area of scar excision and the expanded cervicofacial flap were obtained by using this measuring system in a young patient with scar contracture of the face." | 1.31 | Assessment of facial tissue expansion with three-dimensional digitizer scanning. ( Ji, Y; Lineaweaver, WC; Schwartz, J; Stile, F; Zhang, F, 2002) |
"Although alopecia areata is a common problem among children, many misdiagnoses for this condition can happen." | 1.31 | Striae distensae-like lesions. A cause of scarring alopecia among children. ( Al-Nuaimy, AA; Al-Waiz, MM; Sharquie, KE, 2002) |
"To better define the pathogenesis of acne keloidalis (AK)." | 1.31 | Acne keloidalis is a form of primary scarring alopecia. ( Homoky, C; Pratt, L; Sau, P; Sperling, LC, 2000) |
"The conspicuousness of such a scar results from its linear continuity and hairlessness." | 1.31 | Immediate hair transplantation into a newly closed wound to conceal the final scar on the hair-bearing skin. ( Barutçu, A; Seyhan, A; Yoleri, L, 2000) |
"Unsightly scalp scars, refractory to surgical revision, can pose a difficult therapeutic problem." | 1.31 | Micropigmentation as an adjuvant in cosmetic surgery of the scalp. ( Traquina, AC, 2001) |
"The biggest dimension of repaired baldness was 340 cm2, one expander exposed and one failed in expanding after operation and be corrected immediately." | 1.31 | [Treating cicatricial baldness with scalp expanding and hair autografting]. ( Li, AL; Yan, YZ; Yu, MS, 2001) |
"The quality of the scar was excellent in the majority of cases." | 1.31 | Face lifts with hidden scars: the vertical U incision. ( Brady, JA; Chiou, P; Marchac, D, 2002) |
"The visible linear scar of the scalp is a cosmetically serious complication of a scalp incision in scalp surgery, forehead lift, and craniofacial surgery, especially on the temporal scalp." | 1.30 | Prevention and treatment of wide scar and alopecia in the scalp: wedge excision and double relaxation suture. ( Burm, JS; Oh, SJ, 1999) |
"POEMS syndrome is a rare condition with cutaneous manifestations commonly including angiomas, hypertrichosis, hyperpigmentation, and thickening of the skin." | 1.30 | POEMS syndrome: cicatricial alopecia as an unusual cutaneous manifestation associated with an underlying plasmacytoma. ( Feller, AC; Meigel, W; Mensing, H; Ramsauer, J; Stemm, AV; Weichenthal, M, 1999) |
"Anterior scalp scars may be improved by punch excision and micrografting." | 1.30 | Hair repair surgery. Corrective measures for improvement of older large-graft procedures and scalp scars. ( Swinehart, JM, 1999) |
"Although hidden, the scar placement permits full correction of redundant neck skin." | 1.30 | Hiding the posterior scar in rhytidectomy: the omega incision. ( Little, JW, 1999) |
"Malignant fibrous histiocytoma (MFH) which is usually originated from muscles and deep fascia and rarely from the subcutaneous tissue is the most common soft tissue sarcoma; and it frequently invades the extremities." | 1.30 | Malignant fibrous histiocytoma developing in a burn scar. ( Baş, L; Kabukçuoğlu, F; Ozcan, H; Sanus, Z; Turgut, G; Uğurlu, K, 1999) |
"45 cases with baldness following burn from 1988 to 1998 were reported." | 1.30 | [The clinical application of scalp expansion in the repair of cicatricial baldness in children]. ( Gao, Z; Liu, Y; Yang, J, 1999) |
"Temporary hair loss is well accepted as a possible result of psoriatic plaques." | 1.29 | [Scarring psoriatic alopecia]. ( Bonsmann, G; Kretzschmar, L; Luger, TA; Metze, D; Schwarz, T, 1995) |
"Dermoids are congenital subcutaneous cysts, which gradually flatten and scar over a number of years." | 1.28 | Congenital inclusion dermoid cysts of the scalp. ( Darley, C; Dawber, RP; Sinclair, RD, 1992) |
"Radiation-induced meningiomas have a characteristic biological behaviour, so that their recognition is important as regards follow-up." | 1.28 | A scalp lesion over an extracerebral mass: a sign of a radiation-induced meningioma. ( Climent, V; García Santos, JM, 1992) |
"In 1885 Brocq described a type of scarring alopecia he called pseudopelade (PPB), whose character as a separate disease entity has been denied in recent decades." | 1.28 | [The Brocq pseudopelade--a disease picture or disease entity]. ( Bergner, T; Braun-Falco, O; Heilgemeir, GP, 1989) |
"In six patients, burn scar of the scalp caused by direct exposure to fire in their infancy was a pathogenesis underlying the development of the malignancy, and the time interval was estimated to be an average of 53 years." | 1.28 | [Surgical management of squamous-cell carcinomas arising in burn scar of the scalp]. ( Kikuchi, K; Konno, A; Kowada, M; Mineura, K; Sakamoto, T, 1989) |
"The metaplastic synovial cyst (synovial metaplasia of the skin) is a recently described intradermal cyst lined by a membrane that resembles hyperplastic synovium." | 1.27 | Metaplastic synovial cyst after partial excision of nevus sebaceus. ( Sexton, FM; Stern, DR, 1988) |
"Facial burn scars are difficult to conceal and often preclude an aesthetic rehabilitation of the patient." | 1.27 | The temporal island scalp flap for management of facial burn scars. ( Argenta, LC; Friedman, RJ; Marks, MW; Thornton, JW, 1988) |
"41 cases with scarring alopecia seen from 1979 to 1983 were analyzed and differentiated." | 1.27 | Pseudopelade of Brocq. ( Bergner, T; Braun-Falco, O; Imai, S; Schmoeckel, C; Steger, O, 1986) |
"A 17-year-old boy had a large, scarred area of alopecia from a thermal burn." | 1.26 | Scalp reduction for alopecia. ( Roenigk, HH; Schultz, BC, 1979) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 67 (18.82) | 18.7374 |
1990's | 50 (14.04) | 18.2507 |
2000's | 81 (22.75) | 29.6817 |
2010's | 108 (30.34) | 24.3611 |
2020's | 50 (14.04) | 2.80 |
Authors | Studies |
---|---|
Zhang, YJ | 1 |
Chen, YM | 1 |
Shao, XY | 1 |
Liu, L | 2 |
Pu, YH | 1 |
Zhang, LZ | 1 |
Chen, JY | 1 |
Chen, J | 2 |
Han, Q | 1 |
Zeng, J | 1 |
Liu, Y | 6 |
Yin, J | 1 |
Sun, P | 2 |
Wu, Y | 1 |
Garg, VK | 1 |
Sinha, S | 1 |
Sarkar, R | 1 |
COLIN, R | 1 |
DOSSA, J | 1 |
POUS, JG | 1 |
Danielson, JR | 1 |
Walter, RJ | 1 |
Samrao, A | 1 |
Lyon, L | 1 |
Mirmirani, P | 4 |
Massarelli, O | 1 |
Vaira, LA | 1 |
De Riu, G | 1 |
Mishra, P | 1 |
Patil, A | 1 |
Sinclair, R | 5 |
Gold, M | 1 |
Rudnicka, L | 2 |
Grabbe, S | 1 |
Goldust, M | 1 |
Jamerson, TA | 1 |
Conover Talbot, C | 1 |
Dina, Y | 1 |
Kwatra, SG | 1 |
Garza, LA | 1 |
Aguh, C | 2 |
Cuadrado, ML | 1 |
González-García, N | 1 |
Porta-Etessam, J | 1 |
de Andrade Lima, MMD | 1 |
Benez, M | 1 |
Gamonal, SBL | 1 |
Melo, DF | 1 |
Tortelly, VD | 1 |
Frattini, S | 1 |
de Andrade Lima, EV | 1 |
Liu, S | 1 |
Tang, Y | 1 |
Ding, J | 1 |
Chu, F | 1 |
Yu, Z | 1 |
Ma, X | 2 |
Venter, TH | 1 |
Parker, GR | 1 |
Rogers, AD | 1 |
Clapham, LE | 1 |
Mende, K | 1 |
Park, JH | 3 |
Ho, YH | 1 |
Manonukul, K | 1 |
Ali, S | 1 |
Collins, M | 1 |
Taylor, SC | 2 |
Kelley, K | 1 |
Stratton, E | 1 |
Senna, M | 1 |
Miteva, M | 2 |
Nadji, M | 1 |
Billero, V | 1 |
LaSenna, C | 1 |
Nattkemper, L | 1 |
Romanelli, P | 1 |
Sons, JS | 3 |
Chateau, AV | 3 |
Douglas, A | 1 |
Romisher, A | 1 |
Cohen, A | 1 |
Zaya, R | 1 |
Wang, J | 5 |
Suriano, J | 1 |
Zachian, R | 1 |
Nikbakht, N | 1 |
Wollina, U | 1 |
Park, G | 1 |
Kim, J | 3 |
Kim, T | 1 |
Park, J | 1 |
Pearce, J | 1 |
Al-Wahab, Y | 1 |
Brent, G | 1 |
Natkunarajah, J | 1 |
Larrondo, J | 1 |
McMichael, AJ | 3 |
Sode, T | 1 |
Ogwumike, E | 1 |
Hosler, GA | 1 |
Khalid, I | 1 |
Riopelle, AM | 1 |
Jeong, D | 1 |
Boyd, AY | 1 |
Schanbacher, CF | 1 |
Pitch, MA | 1 |
Sperling, LC | 5 |
Liu, J | 1 |
Wang, Y | 1 |
Jackson, TK | 1 |
Sow, Y | 1 |
Ayoade, KO | 1 |
Seykora, JT | 1 |
Ogunleye, T | 1 |
Heymann, WR | 1 |
Le, D | 1 |
Gan, Y | 1 |
Mao, X | 1 |
Qu, Q | 1 |
Fan, Z | 1 |
Liu, B | 1 |
Zhang, J | 2 |
Hu, Z | 1 |
Miao, Y | 1 |
Kuka Epstein, G | 1 |
Epstein, J | 1 |
Tan, TL | 1 |
Doytcheva, K | 1 |
Guitart, J | 2 |
Gerami, P | 2 |
Yazdan, P | 2 |
Ramot, Y | 1 |
Bertolini, M | 1 |
Boboljova, M | 1 |
Uchida, Y | 1 |
Paus, R | 2 |
Jiang, W | 2 |
Wang, M | 2 |
Wang, B | 3 |
Gassenmaier, M | 1 |
Bösmüller, H | 1 |
Metzler, G | 1 |
Fernandez-Flores, A | 1 |
Maguire, M | 1 |
Drumm, C | 1 |
Woods, G | 1 |
Mullally, W | 1 |
Redmond, M | 1 |
Grogan, L | 1 |
O'Kane, M | 1 |
Sorger, C | 1 |
Mentzel, J | 1 |
Simon, JC | 1 |
Treudler, R | 1 |
Trindade de Carvalho, L | 1 |
Meah, N | 1 |
Wall, D | 1 |
Sullivan, JV | 1 |
Dziewulski, P | 1 |
Shelley, OP | 1 |
El Shabrawi-Caelen, L | 1 |
McMichael, A | 6 |
Eginli, A | 2 |
Cooley, J | 2 |
Seyhan, T | 1 |
Kapi, E | 1 |
Mohmand, MH | 1 |
Ahmad, M | 2 |
Sun, H | 1 |
Yao, P | 1 |
Shi, Y | 1 |
Char, S | 1 |
Wang, X | 1 |
Yao, J | 1 |
Yang, C | 1 |
Tan, X | 2 |
Chen, L | 1 |
Jia, L | 1 |
Olshinka, A | 1 |
Ad-El, D | 1 |
Kalish, E | 1 |
Shay, T | 1 |
Yaacobi, DS | 1 |
Lorei, NC | 1 |
Sullivan, JF | 1 |
Lennon, RP | 1 |
Milder, EA | 1 |
Roman, JW | 1 |
Agaoglu, G | 1 |
Özer, F | 1 |
Karademir, S | 1 |
Agaoglu, E | 1 |
Erol, O | 1 |
Olsen, EA | 4 |
Harries, M | 1 |
Tosti, A | 6 |
Bergfeld, W | 2 |
Blume-Peytavi, U | 1 |
Callender, V | 1 |
Chasapi, V | 1 |
Correia, O | 1 |
Cotsarelis, G | 2 |
Dhurat, R | 1 |
Dlova, N | 1 |
Doche, I | 1 |
Enechukwu, N | 1 |
Grimalt, R | 1 |
Itami, S | 1 |
Hordinsky, M | 1 |
Khobzei, K | 1 |
Lee, WS | 2 |
Malakar, S | 1 |
Messenger, A | 1 |
Ovcharenko, Y | 1 |
Papanikou, S | 1 |
Pinto, GM | 1 |
Piraccini, BM | 1 |
Pirmez, R | 1 |
Reygagne, P | 1 |
Roberts, J | 1 |
Saceda-Corralo, D | 1 |
Shapiro, J | 1 |
Silyuk, T | 1 |
Soares, RO | 1 |
Souissi, A | 1 |
Vogt, A | 1 |
Washenik, K | 1 |
Zlotogorski, A | 1 |
Canfield, D | 1 |
Vano-Galvan, S | 1 |
Berenguer, B | 1 |
García, T | 1 |
Lorca-García, C | 1 |
San-Basilio, M | 1 |
Tsao, SB | 1 |
Jong, LR | 1 |
Su, YC | 1 |
Kuo, YR | 1 |
Dothard, E | 1 |
Bagayoko, CW | 1 |
Huang, K | 1 |
Daniel, A | 1 |
Lim, JH | 1 |
Siow, WS | 1 |
Tan, LS | 1 |
Elston, DM | 1 |
Tolkachjov, SN | 1 |
Chaudhry, HM | 1 |
Camilleri, MJ | 1 |
Torgerson, RR | 1 |
Li, Y | 1 |
Li, W | 2 |
Liu, C | 1 |
Peng, P | 1 |
Song, B | 1 |
Xia, W | 2 |
Yi, C | 2 |
Lu, K | 2 |
Su, Y | 1 |
Tan, T | 1 |
Vazquez-Herrera, NE | 1 |
Eber, AE | 1 |
Martinez-Velasco, MA | 1 |
Perper, M | 1 |
Cervantes, J | 1 |
Verne, SH | 1 |
Magno, RJ | 1 |
Nouri, K | 1 |
Harb, JN | 1 |
Owens, AL | 1 |
Potter, KM | 1 |
Montuno, M | 1 |
De Jesus, RO | 1 |
Konda, S | 1 |
Khouri, KS | 1 |
Cardoso, E | 1 |
Khouri, RK | 1 |
Chang, H | 1 |
Ding, Y | 1 |
Wang, P | 1 |
Wang, Q | 1 |
Lin, Y | 2 |
Li, B | 2 |
Katoulis, AC | 1 |
Diamanti, K | 1 |
Sgouros, D | 1 |
Liakou, AI | 1 |
Bozi, E | 1 |
Avgerinou, G | 1 |
Panayiotides, I | 1 |
Rigopoulos, D | 2 |
Su, HJ | 1 |
Cheng, AY | 1 |
Liu, CH | 1 |
Chu, CB | 1 |
Lee, CN | 1 |
Hsu, CK | 1 |
Lee, JY | 1 |
Yang, CC | 1 |
Sundberg, JP | 1 |
Hordinsky, MK | 2 |
Lenzy, YM | 2 |
Christiano, AM | 1 |
McGregor, T | 1 |
Stenn, KS | 1 |
Sivamani, RK | 1 |
Pratt, CH | 1 |
King, LE | 1 |
Gomes, RC | 1 |
Guirro, ECO | 1 |
Gonçalves, AC | 1 |
Farina Junior, JA | 1 |
Murta Junior, LO | 1 |
Guirro, RRJ | 1 |
van Niekerk, G | 1 |
Adams, S | 1 |
Rode, H | 1 |
Zimmerman, B | 1 |
Ivars, M | 1 |
Cordoro, KM | 1 |
Subash, J | 1 |
Alexander, T | 1 |
Beamer, V | 1 |
Theroux, ZA | 1 |
Blechman, AB | 1 |
Russell, MA | 1 |
Paolino, G | 1 |
Panetta, C | 1 |
Didona, D | 1 |
Donati, M | 1 |
Donati, P | 1 |
Chen, C | 1 |
Sun, Z | 2 |
Arif, T | 1 |
Adil, M | 1 |
Suhail Amin, S | 1 |
Alam, M | 2 |
Lin, J | 1 |
Saknite, I | 1 |
Valdebran, M | 1 |
Balu, M | 1 |
Lentsch, G | 1 |
Williams, JN | 1 |
Koenig, K | 1 |
Tromberg, BJ | 1 |
Atanaskova Mesinkovska, N | 1 |
You, SH | 2 |
Kim, NR | 1 |
Prohaska, J | 1 |
Demaree, E | 1 |
Powers, J | 1 |
Cook, C | 1 |
Xiao, H | 1 |
Deng, K | 1 |
Liu, R | 1 |
Chen, Z | 1 |
Gao, Y | 1 |
Cen, Y | 1 |
Xu, X | 2 |
Tang, S | 2 |
Wu, X | 1 |
Cheng, H | 1 |
Shen, H | 1 |
Tang, L | 1 |
Zhou, J | 1 |
Jia, M | 1 |
Li, J | 1 |
Plotczyk, M | 1 |
Martínez-Martín, MS | 1 |
Izeta, A | 1 |
Jimenez, F | 1 |
Wada, N | 1 |
Uchi, H | 1 |
Furue, M | 1 |
Malki, L | 1 |
Sarig, O | 1 |
Romano, MT | 1 |
Méchin, MC | 1 |
Peled, A | 1 |
Pavlovsky, M | 1 |
Warshauer, E | 1 |
Samuelov, L | 1 |
Uwakwe, L | 1 |
Briskin, V | 1 |
Mohamad, J | 1 |
Gat, A | 1 |
Isakov, O | 1 |
Rabinowitz, T | 1 |
Shomron, N | 1 |
Adir, N | 1 |
Simon, M | 1 |
Dlova, NC | 1 |
Betz, RC | 1 |
Sprecher, E | 1 |
Garcia-Robledo, JE | 1 |
Aragón, CC | 1 |
Nieto-Aristizábal, I | 1 |
Vásquez, S | 1 |
Montoya, C | 1 |
Tobón, GJ | 1 |
Fukuyama, M | 1 |
Ohyama, M | 1 |
Kaya İslamoğlu, ZG | 1 |
Uysal, E | 1 |
Durgun, M | 1 |
Aksam, E | 1 |
Hou, Z | 1 |
Lee, PK | 1 |
Yoo, H | 1 |
Moh, J | 1 |
Park, JU | 1 |
Divine, J | 1 |
Rudnick, EW | 1 |
Lien, M | 1 |
Croley, JAA | 1 |
Hirshburg, JM | 1 |
Wagner, RF | 1 |
Nirmal, B | 1 |
George, R | 1 |
Eftekhari, H | 1 |
Azimi, SZ | 1 |
Rafiei, R | 1 |
Darjani, A | 1 |
Alizadeh, N | 1 |
Rafiei, E | 1 |
Ghadarjani, R | 1 |
Gharaei Nejad, K | 1 |
Simsek, T | 1 |
Eroglu, L | 1 |
Horenstein, MG | 1 |
Bacheler, CJ | 1 |
Uhlenhake, EE | 1 |
Mehregan, DM | 1 |
László, FG | 1 |
Rogers, NE | 3 |
Kluger, N | 1 |
Cavelier-Balloy, B | 1 |
Assouly, P | 1 |
Filbrandt, R | 1 |
Rufaut, N | 1 |
Jones, L | 1 |
Cascio, A | 1 |
Torina, A | 1 |
Valenzise, M | 1 |
Blanda, V | 1 |
Camarda, N | 1 |
Bombaci, S | 1 |
Iaria, C | 1 |
De Luca, F | 1 |
Wasniewska, M | 1 |
Hundeshagen, G | 2 |
Assadov, KF | 1 |
Podmelle, F | 1 |
Jung, S | 2 |
Oh, SJ | 3 |
Hoon Koh, S | 1 |
Shen, CA | 1 |
Chai, JK | 1 |
Zhang, L | 1 |
Li, DJ | 1 |
Tuo, XY | 1 |
Cai, JH | 1 |
Wang, SJ | 1 |
Zhu, H | 1 |
Cai, JD | 1 |
Agrawal, V | 1 |
Acharya, H | 1 |
Agarwal, P | 1 |
Sekhon, V | 1 |
Sharma, D | 1 |
Buchwach, KA | 1 |
Donovan, JC | 2 |
Du, Q | 1 |
Zhang, T | 1 |
Loh, CC | 1 |
Su, JC | 1 |
Daniel, BS | 1 |
Venugopal, SS | 1 |
Rhodes, LM | 1 |
Intong, LR | 1 |
Law, MG | 1 |
Murrell, DF | 1 |
Moh, JS | 1 |
Lee, SY | 1 |
Lampeter, W | 1 |
Delacerda, AB | 1 |
Chandler, RG | 1 |
Wells, MJ | 1 |
Vindhya, PL | 1 |
Parodi, A | 1 |
Cozzani, E | 1 |
Torres, F | 2 |
Huang, X | 1 |
Liu, K | 1 |
Gu, B | 1 |
Li, Q | 1 |
Esposito, C | 1 |
Escolino, M | 1 |
Paternoster, M | 1 |
Buccelli, C | 1 |
Graziano, V | 1 |
Falco, M | 1 |
Alicchio, F | 1 |
Cerulo, M | 1 |
Settimi, A | 1 |
Savanelli, A | 1 |
Ogunleye, TA | 1 |
Yang, TL | 1 |
Ko, JY | 1 |
Lou, PJ | 1 |
Wang, CP | 1 |
Hsiao, TY | 1 |
Madu, P | 1 |
Kundu, RV | 1 |
Abada, H | 1 |
Aktouf, A | 1 |
Delaunay, F | 1 |
Lievain, L | 1 |
Auquit-Auckbur, I | 1 |
Huang, YL | 1 |
Chang, SL | 1 |
Lee, MC | 1 |
Chang, CH | 1 |
Hu, S | 1 |
Gold, MH | 1 |
Sanada, Y | 1 |
Yabuuchi, T | 1 |
Yoshioka, H | 1 |
Kubota, H | 1 |
Kato, A | 1 |
Dan, L | 1 |
Relic, J | 1 |
Moulton-Barrett, R | 1 |
Vanderschelden, B | 1 |
Lacarrubba, F | 1 |
Micali, G | 1 |
Stamatios, G | 1 |
Ioannides, D | 1 |
Yamamoto, K | 1 |
Avignon, S | 1 |
Foletti, JM | 1 |
Guyot, L | 1 |
Si, Y | 1 |
Huang, QH | 1 |
Liang, MJ | 1 |
Jiang, HL | 1 |
Xu, G | 1 |
Zhang, ZG | 1 |
Peng, W | 1 |
Hongwei, Y | 1 |
Li, C | 1 |
Hui, G | 1 |
Xia, Y | 1 |
Hua, L | 1 |
Li, Z | 2 |
Jung, SW | 1 |
Koh, SH | 2 |
Lim, H | 1 |
Wang, HY | 1 |
Wang, MG | 1 |
Yu, G | 1 |
Chu, YJ | 1 |
Wang, K | 1 |
Wei, XP | 1 |
Sun, JW | 1 |
Castelo-Soccio, L | 1 |
Ardigò, M | 1 |
Agozzino, M | 1 |
Franceschini, C | 1 |
Donadio, C | 1 |
Abraham, LS | 1 |
Barbieri, L | 1 |
Sperduti, I | 1 |
Berardesca, E | 1 |
González, S | 1 |
Du, X | 1 |
Xu, W | 1 |
Zhou, X | 1 |
Song, C | 1 |
Fan, W | 1 |
Kolivras, A | 1 |
Thompson, C | 1 |
Bernstein, RM | 1 |
Tandon, YK | 1 |
Somani, N | 1 |
Cevasco, NC | 1 |
Bergfeld, WF | 3 |
Xianjie, M | 1 |
Zheng, Y | 1 |
Ai, Y | 1 |
Guo, S | 2 |
Han, Y | 1 |
Avram, MR | 1 |
Emsen, IM | 2 |
Calikapan, GT | 1 |
Akan, M | 1 |
Karaca, M | 1 |
Aköz, T | 2 |
Fan, J | 3 |
Gan, C | 1 |
Tan, KT | 1 |
Messenger, AG | 1 |
Goldberg, LJ | 1 |
HALPERT, B | 1 |
LAIN, ES | 1 |
Vogel, JE | 1 |
Sukhatme, SV | 1 |
Gottlieb, AB | 1 |
Jiao, P | 1 |
Zhu, S | 1 |
Willey, A | 1 |
Chamlin, S | 1 |
Frieden, IJ | 1 |
Price, VH | 1 |
Wu, JK | 1 |
Rohde, CH | 1 |
Misciali, C | 1 |
Vincenzi, C | 1 |
Duque-Estrada, B | 1 |
Kandamany, N | 1 |
Monk, B | 1 |
Borovicka, JH | 1 |
Thomas, L | 1 |
Prince, C | 1 |
Mehregan, DR | 1 |
Sengul, G | 1 |
Hadi-Kadioglu, H | 1 |
Klinger, M | 1 |
Villani, F | 1 |
Klinger, F | 1 |
Gaetani, P | 1 |
Rodriguez Y Baena, R | 1 |
Levi, D | 1 |
Corva, L | 1 |
Sardesai, SR | 1 |
Kornacka, MK | 1 |
Walas, W | 1 |
Ramanathan, R | 1 |
Nasir, S | 1 |
Aydin, MA | 1 |
Meier, MJ | 1 |
Mutasim, DF | 1 |
Schardey, HM | 1 |
Barone, M | 1 |
Pörtl, S | 1 |
von Ahnen, M | 1 |
von Ahnen, T | 1 |
Schopf, S | 1 |
St Pierre, SA | 1 |
Vercellotti, GM | 1 |
Firoz, BF | 1 |
Goldberg, LH | 1 |
Katz, T | 1 |
Kimyai-Asadi, A | 1 |
Friedman, PM | 1 |
Ruiz, RL | 1 |
Pattisapu, JV | 1 |
Costello, BJ | 1 |
Golden, B | 1 |
Lee, JW | 2 |
Jang, YC | 1 |
Kluk, J | 1 |
Charles-Holmes, R | 1 |
Carr, RA | 1 |
Klein, MB | 1 |
Winter, M | 1 |
Karaçal, N | 1 |
Uraloğlu, M | 1 |
Dindar, T | 1 |
Livaoğlu, M | 1 |
Bonham, J | 1 |
Oddou, L | 1 |
Vouillaume, D | 1 |
Foyatier, JL | 2 |
Dionyssopoulos, A | 1 |
Bach, CA | 1 |
Lapidoth, M | 1 |
Adatto, M | 1 |
Halachmi, S | 1 |
Maillet-Declerck, M | 1 |
Calibre, C | 1 |
Herbaux, B | 1 |
Duquennoy-Martinot, V | 1 |
House, NS | 1 |
Welsh, JP | 1 |
English, JC | 1 |
Childs, JM | 1 |
Wesley, CK | 1 |
Teo, LH | 1 |
Xu, T | 1 |
Unger, RH | 1 |
Unger, WP | 2 |
Ladizinski, B | 1 |
Bazakas, A | 1 |
Selim, MA | 1 |
Seery, GE | 2 |
Komuro, Y | 1 |
Yanai, A | 1 |
Seno, H | 1 |
Ichida, M | 1 |
Inoue, M | 1 |
Miyajima, M | 1 |
Arai, H | 1 |
Sato, K | 1 |
Yotsuyanagi, T | 1 |
Watanabe, Y | 1 |
Yamashita, K | 1 |
Urushidate, S | 1 |
Yokoi, K | 1 |
Sawada, Y | 1 |
Ji, Y | 1 |
Zhang, F | 1 |
Schwartz, J | 1 |
Stile, F | 1 |
Lineaweaver, WC | 1 |
Sharquie, KE | 1 |
Al-Waiz, MM | 1 |
Al-Nuaimy, AA | 1 |
Camarata, JC | 1 |
Wang, PT | 1 |
Tao, X | 1 |
Chen, W | 1 |
Ma, J | 1 |
Bowman, PH | 1 |
Goldman, MP | 1 |
Kolasiñski, J | 1 |
Kolenda, M | 1 |
HOLMES, EM | 1 |
ONIZUKA, T | 1 |
OHMORI, S | 1 |
Solky, B | 1 |
Elenitsas, R | 1 |
Brandy, DA | 2 |
Bauer, BS | 1 |
Margulis, A | 1 |
Ogawa, R | 1 |
Hyakusoku, H | 1 |
Murakami, M | 1 |
Gao, JH | 1 |
Tellioğlu, AT | 1 |
Cimen, K | 1 |
Açar, HI | 1 |
Karaeminoğullar, G | 1 |
Tekdemir, I | 1 |
Bacanli, A | 1 |
Uzun, S | 1 |
Ciftcioglu, MA | 1 |
Alpsoy, E | 1 |
Moussaoui, A | 1 |
Fejjal, N | 1 |
Cantaloube, D | 1 |
Wang, DL | 1 |
Wang, YM | 1 |
Chen, SJ | 1 |
Han, WJ | 1 |
Wei, ZR | 1 |
He, Z | 1 |
Yu, L | 1 |
Luo, S | 1 |
Jain, N | 1 |
Mirakhur, M | 1 |
Flynn, P | 1 |
Choudhari, KA | 1 |
Picard, A | 1 |
Franchi, G | 1 |
Delbecque, M | 1 |
Sergent, B | 1 |
Buis, J | 1 |
Vazquez, MP | 1 |
Inglese, MJ | 1 |
Bergamo, BM | 1 |
Mimoun, M | 1 |
Chaouat, M | 1 |
Picovski, D | 1 |
Serroussi, D | 1 |
Smarrito, S | 1 |
van den Hombergh, P | 1 |
Veeken, HP | 1 |
Scheinfeld, N | 1 |
Frechet, P | 2 |
Voulliaume, D | 1 |
Chichery, A | 1 |
Chekaroua, K | 1 |
Comparin, JP | 1 |
Wang, JP | 1 |
Fan, JC | 1 |
Kwon, OS | 1 |
Kim, MH | 1 |
Park, SH | 1 |
Chung, JH | 1 |
Eun, HC | 1 |
Oh, JK | 1 |
Donelan, MB | 1 |
Garcia, JA | 1 |
Srivastava, M | 1 |
Mikkilineni, R | 1 |
Konstadt, J | 1 |
Drissi Qeytoni, H | 1 |
Nassih, M | 1 |
Rzin, A | 1 |
Jidal, B | 1 |
Yun, SJ | 1 |
Yoon, HJ | 1 |
Lee, SS | 1 |
Kim, SY | 1 |
Lee, JB | 1 |
Lee, SC | 1 |
Won, YH | 1 |
Kim, SJ | 1 |
Goodman, GJ | 1 |
Baron, JA | 1 |
Dinh, HV | 1 |
Martinick, J | 1 |
ARDAO, HA | 1 |
Lasheen, AE | 1 |
Saad, K | 1 |
Raslan, M | 1 |
Blackwell, KE | 1 |
Rawnsley, JD | 1 |
Motamed, S | 1 |
Niazi, F | 1 |
Atarian, S | 1 |
Motamed, A | 1 |
Severs, GA | 1 |
Griffin, T | 1 |
Werner-Wasik, M | 1 |
Lipsker, D | 1 |
Boeckler, P | 1 |
Cribier, B | 1 |
Fernandes Rodrigues, JC | 1 |
Pinto Soares, A | 1 |
Garcia E Silva, L | 1 |
Norwood, OT | 2 |
Shiell, RC | 1 |
Morrison, ID | 1 |
Maillard, GF | 1 |
Landolt, A | 1 |
Manders, EK | 2 |
Schenden, MJ | 1 |
Furrey, JA | 1 |
Hetzler, PT | 1 |
Davis, TS | 1 |
Graham, WP | 1 |
Ohmori, K | 3 |
Johnson, CM | 1 |
Adamson, PA | 1 |
Anderson, JR | 1 |
Guaricci, N | 1 |
Gasperoni, C | 1 |
De Stefano, C | 1 |
Proia, G | 1 |
Standoli, L | 1 |
Oh, S | 1 |
Tok, S | 1 |
Allemann, J | 1 |
Prevost, A | 1 |
Schmid, UD | 1 |
Bricout, N | 2 |
Raulo, Y | 1 |
Geissmann, O | 1 |
Wechsler, J | 1 |
Buncke, HJ | 1 |
Hoffman, WY | 1 |
Alpert, BS | 1 |
Gordon, L | 1 |
Stefani, AE | 1 |
Hanke, CW | 2 |
Klöti, J | 1 |
Pochon, JP | 1 |
Ceilley, RI | 1 |
Vallis, CP | 1 |
Knight, TE | 1 |
Robinson, HM | 1 |
Sina, B | 1 |
Raja, A | 1 |
Subramanian, MV | 1 |
Cheeramattam, PA | 1 |
McCray, MK | 1 |
Roenigk, HH | 2 |
Takayanagi, S | 1 |
Tsukie, T | 1 |
Ho, C | 1 |
Nguyen, Q | 1 |
Lask, G | 1 |
Lowe, N | 1 |
Dzubow, LM | 1 |
Stough, DB | 1 |
Spencer, DM | 1 |
Schauder, CS | 1 |
Kretzschmar, L | 1 |
Bonsmann, G | 1 |
Metze, D | 1 |
Luger, TA | 1 |
Schwarz, T | 1 |
Lange-Ionescu, S | 1 |
Frosch, PJ | 1 |
Kossard, S | 2 |
Wang, CZ | 1 |
Niu, XT | 1 |
Cheng, DM | 1 |
Long, J | 1 |
Ma, E | 1 |
Liu, F | 1 |
Kelly, RI | 1 |
Marsden, RA | 1 |
Munro, IR | 1 |
Fearon, JA | 1 |
Auletta, MJ | 1 |
Matarasso, SL | 1 |
Glogau, RG | 1 |
Tromovitch, TA | 1 |
Zagarella, S | 1 |
Akita, S | 1 |
Hirano, A | 1 |
Eren, S | 1 |
Hess, J | 1 |
Larkin, GC | 1 |
Ko, T | 1 |
Tada, H | 1 |
Hatoko, M | 1 |
Muramatsu, T | 1 |
Shirai, T | 1 |
Erdoğan, B | 1 |
Görgü, M | 1 |
Aslan, G | 1 |
Trüeb, RM | 1 |
Jackow, CM | 1 |
Papadopoulos, E | 1 |
Nelson, B | 1 |
Tschen, JA | 1 |
Heatherington, G | 1 |
Duvic, M | 1 |
Hwang, SM | 1 |
Ahn, SK | 1 |
Soejima, K | 1 |
Nozaki, M | 1 |
Sasaki, K | 1 |
Takeuchi, M | 1 |
Negishi, N | 1 |
Can, Z | 1 |
Yilmaz, S | 1 |
Riza, A | 1 |
Apaydin, EI | 1 |
Kuzu, I | 1 |
Papay, FA | 1 |
Stein, J | 1 |
Luciano, M | 1 |
Zins, JE | 1 |
Burm, JS | 1 |
Kimata, Y | 1 |
Sekido, M | 1 |
Ebihara, S | 1 |
Chen, CY | 1 |
Uchiyama, K | 1 |
Hayashi, R | 1 |
Nakatsuka, T | 1 |
Harii, K | 4 |
Yavuzer, R | 1 |
Jackson, IT | 1 |
Okamoto, K | 1 |
Ito, J | 1 |
Sakai, K | 1 |
Weichenthal, M | 1 |
Stemm, AV | 1 |
Ramsauer, J | 1 |
Mensing, H | 1 |
Feller, AC | 1 |
Meigel, W | 1 |
Shan, S | 2 |
Gao, G | 1 |
Zhang, D | 1 |
Wang, S | 1 |
Long, D | 1 |
Aderriotis, D | 1 |
Sàndor, GK | 1 |
Liu, X | 1 |
Zhong, Q | 1 |
Xiao, Z | 1 |
Swinehart, JM | 1 |
Little, JW | 1 |
Uğurlu, K | 1 |
Turgut, G | 1 |
Kabukçuoğlu, F | 1 |
Ozcan, H | 1 |
Sanus, Z | 1 |
Baş, L | 1 |
Bozzetti, A | 1 |
Biglioli, F | 1 |
Salvato, G | 1 |
Brusati, R | 1 |
Bennaceur, S | 1 |
Bayonne, E | 1 |
Munier, N | 1 |
Buisson, T | 1 |
Teillac-Hamel, D | 1 |
Chrétien-Marquet, B | 1 |
Homoky, C | 1 |
Pratt, L | 1 |
Sau, P | 1 |
Seyhan, A | 1 |
Yoleri, L | 1 |
Barutçu, A | 1 |
Field, LM | 1 |
Podda, M | 1 |
Spieth, K | 1 |
Kaufmann, R | 1 |
Mentzel, M | 1 |
Ebinger, T | 1 |
Hoss, H | 1 |
Halder, A | 1 |
Kinzl, L | 1 |
Wachter, NJ | 1 |
Schön, MP | 1 |
Reifenberger, J | 1 |
Gantke, B | 1 |
Megahed, M | 1 |
Lehmann, P | 1 |
Traquina, AC | 1 |
Powell, J | 1 |
Dawber, RP | 2 |
Hu, H | 1 |
Sun, G | 1 |
Liu, Z | 1 |
Li, AL | 1 |
Yu, MS | 1 |
Yan, YZ | 1 |
Biswas, G | 1 |
Lohani, I | 1 |
Chari, PS | 1 |
Korotkikh, NG | 1 |
Khodorkovskiĭ, MA | 1 |
Petrov, BV | 1 |
Marchac, D | 1 |
Brady, JA | 1 |
Chiou, P | 1 |
Yang, J | 1 |
Gao, Z | 1 |
Hock, MO | 1 |
Ooi, SB | 1 |
Saw, SM | 1 |
Lim, SH | 1 |
Singer, AJ | 1 |
Strong, AM | 1 |
Dardour, JC | 1 |
Noury-Duperrat, G | 1 |
Dufourmentel, C | 1 |
Paletta, FX | 1 |
Torii, S | 1 |
Sekiguchi, J | 1 |
Schultz, BC | 1 |
Shafir, R | 1 |
Slutzki, S | 1 |
Bornstein, LA | 1 |
Tsur, H | 1 |
Bart, RS | 1 |
Schrager, D | 1 |
Kopf, AW | 1 |
Bromberg, J | 1 |
Dubin, N | 1 |
Taylor, JW | 1 |
Wilmore, DW | 1 |
Peterson, HD | 1 |
Pruitt, BA | 1 |
Sinclair, RD | 1 |
Darley, C | 1 |
García Santos, JM | 1 |
Climent, V | 1 |
Darzi, MA | 1 |
Iqbal, S | 1 |
Chowdri, NA | 1 |
Hafiz, A | 1 |
Stratis, JP | 1 |
Ramer, JC | 1 |
Lehman, RA | 1 |
Ladda, RL | 1 |
van der Veen, R | 1 |
Pulles, HJ | 1 |
Cotterill, PC | 1 |
Kumar, S | 1 |
Puri, V | 1 |
Gupta, S | 1 |
Madazimov, MM | 1 |
Grishkevich, VM | 1 |
Moroz, VIu | 1 |
Vaganova, NA | 1 |
Tao, ZL | 1 |
Sadove, AM | 1 |
Moore, TS | 1 |
Eppley, BL | 1 |
Jin, YT | 1 |
Mayer, TG | 1 |
Fleming, RW | 1 |
Ai, YF | 1 |
Braun-Falco, O | 2 |
Bergner, T | 2 |
Heilgemeir, GP | 1 |
Akuamoa-Boateng, E | 1 |
Stindt, D | 1 |
Machtens, E | 1 |
Bonorden, SW | 1 |
Sakamoto, T | 1 |
Mineura, K | 1 |
Kikuchi, K | 1 |
Kowada, M | 1 |
Konno, A | 1 |
Lyons, GB | 1 |
Milroy, BC | 1 |
Lendvay, PG | 1 |
Teston, LM | 1 |
Moscona, R | 1 |
Ullmann, Y | 1 |
Bergman, R | 1 |
Friedman-Birnbaum, R | 1 |
Saouma, S | 1 |
Servant, JM | 1 |
Banzet, P | 1 |
Boyd, JB | 1 |
Stern, DR | 1 |
Sexton, FM | 1 |
Hemmer, KM | 1 |
Marsh, JL | 1 |
Picker, S | 1 |
Guyuron, B | 1 |
Davies, B | 1 |
Hallock, GG | 1 |
Marks, MW | 1 |
Friedman, RJ | 1 |
Thornton, JW | 1 |
Argenta, LC | 1 |
Mahe, E | 1 |
Banal, A | 1 |
Le Doussal, V | 1 |
Harfaoui-Chanaoui, T | 1 |
Farges, P | 1 |
Roenigk, RK | 1 |
Wheeland, RG | 1 |
Prendiville, JS | 1 |
Esterly, NB | 1 |
Nordström, RE | 1 |
Nordström, RM | 1 |
Pierard-Franchimont, C | 1 |
Pierard, GE | 1 |
Rizzetto-Stubel, A | 1 |
Ellenbogen, R | 1 |
Imai, S | 1 |
Schmoeckel, C | 1 |
Steger, O | 1 |
Zhang, JQ | 1 |
Wang, SY | 1 |
Beutner, KR | 1 |
Baudet, J | 1 |
Lemaire, JM | 1 |
Legroux, P | 1 |
Vidal, L | 1 |
Sargos, P | 1 |
de Conninck, L | 1 |
Goumain, AJ | 1 |
Golitz, LE | 1 |
Shapiro, L | 1 |
Hurwitz, E | 1 |
Stritzler, R | 1 |
Letterman, G | 1 |
Schurter, M | 1 |
Ebner, H | 1 |
Omori, K | 1 |
Omori, S | 1 |
Glanz, S | 1 |
Hofmeier, G | 1 |
López-Tello, CS | 1 |
Aron, R | 1 |
Gordon, W | 1 |
Maguire, CP | 1 |
Chamberlain, JL | 1 |
Bard, JW | 1 |
Berger, RA | 1 |
Orentrich, N | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients With Biopsy-proven Forms of Lichen Planus Not Adequately Controlled With Topical Therapies - PRELUDE[NCT04300296] | Phase 2 | 111 participants (Actual) | Interventional | 2020-07-27 | Completed | ||
Evaluation of the Postoperative Effect of Expanded Pedicled Deltopectoral Flap to Repair the Facial-Cervical Scars[NCT03735641] | 50 participants (Anticipated) | Observational | 2018-10-01 | Enrolling by invitation | |||
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)[NCT03016715] | Phase 2 | 8 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)[NCT02960997] | Phase 2 | 8 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
Development and Validation of an Investigator Global Assessment Score for Keratosis Pilaris[NCT05535517] | 15 participants (Anticipated) | Observational | 2022-08-13 | Recruiting | |||
Barriers to Healthcare and Quality of Life for Central Centrifugal Cicatricial Alopecia Patients[NCT03044782] | 34 participants (Actual) | Observational [Patient Registry] | 2016-08-31 | Completed | |||
A Method of Calculating the Shortest Incision for Internal Fixation of Zygomatic Arch Fracture: Sideburns Mini Incision[NCT05381337] | 80 participants (Actual) | Interventional | 2021-01-01 | Completed | |||
Single-center, Prospective, Non-Randomized Control Clinical Trial of Retro-Auricular Single-Site Endoscopic Versus Open Surgery in Patients With Early Stage Papillary Thyroid Carcinoma[NCT05263141] | 80 participants (Anticipated) | Interventional | 2022-03-01 | Recruiting | |||
Triamcinolone Acetonide as an Adjuvant to Pre-emptive Scalp Infiltration for Relief of Post-craniotomy Pain in Adults[NCT06069804] | Phase 4 | 130 participants (Anticipated) | Interventional | 2023-09-25 | Recruiting | ||
Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases[NCT01890278] | 60 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | |||
Radiation- Induced Alopecia in Patients Undergoing Radiation Therapy to the Brain: A Prospective Clinical and Dosimetric Study of Primary and Metastatic Brain Tumour Patients[NCT03543020] | 25 participants (Actual) | Observational | 2017-07-17 | Terminated (stopped due to inadequate patient number) | |||
Easy Way of Choosing Rectangular Expander and Getting Maximum Benefit From Expanded Tissue[NCT03544697] | 19 participants (Actual) | Observational | 2013-01-31 | Completed | |||
A Pilot Study Comparing Cutaneous Scarring When Scalpel Versus Cautery is Used to Make Skin Incisions[NCT00803140] | 4 participants (Actual) | Interventional | 2008-11-30 | Terminated (stopped due to Slow accrual of subject enrollment.) | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Number of treatment responders at week 16, where response is defined as an Investigator's Global Assessment (IGA) score of 2 or lower at Week 16. IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Minimal; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best score and 4 being worst score. CLP=Cutaneous lichen planus, MLP=Mucosal lichen planus, LPP=Lichen planopilaris. Posterior median and 95% credible interval (instead of 95% confidence interval) were derived using Bayesian method based on beta-binomial model. (NCT04300296)
Timeframe: Baseline up to week 16
Intervention | percentage of participants (Median) |
---|---|
AIN457 300 mg Q4W - TP 1 - CLP Cohort | 44.0 |
Placebo - TP 1 - CLP Cohort | 58.2 |
AIN457 300 mg Q4W - TP 1 - MLP Cohort | 37.5 |
Placebo - TP 1 - MLP Cohort | 23.1 |
AIN457 300 mg Q4W - TP 1 - LPP Cohort | 37.6 |
Placebo - TP 1 - LPP Cohort | 30.9 |
The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=>50% of total body surface (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 2 0 score | Week 16 0 score | Week 16 1 score | Week 16 2 score | Week 16 3 score | Week 16 4 score | Week 16 5 score | Week 20 0 score | Week 20 1 score | Week 20 2 score | Week 20 3 score | Week 20 4 score | Week 20 5 score | Week 24 0 score | Week 24 1 score | Week 24 2 score | Week 24 3 score | Week 24 4 score | Week 24 5 score | Week 28 0 score | Week 28 1 score | Week 28 2 score | Week 28 3 score | Week 28 4 score | Week 28 5 score | Week 32 0 score | Week 32 1 score | Week 32 2 score | Week 32 3 score | Week 32 4 score | Week 32 5 score | |
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort | 0 | 0 | 0 | 3 | 3 | 4 | 0 | 0 | 0 | 3 | 2 | 3 | 2 | 0 | 0 | 2 | 2 | 4 | 2 | 0 | 0 | 2 | 3 | 3 | 2 | 0 | 1 | 0 | 4 | 2 | 2 |
The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=>50% of total body surface (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline 0 Score | Baseline 1 score | Baseline 2 score | Baseline 3 score | Baseline 4 score | Baseline 5 score | Week 2 0 score | Week 2 1 score | Week 2 2 score | Week 2 3 score | Week 2 4 score | Week 2 5 score | Week 4 0 score | Week 4 1 score | Week 4 2 score | Week 4 3 score | Week 4 4 score | Week 4 5 score | Week 8 0 score | Week 8 1 score | Week 8 2 score | Week 8 3 score | Week 8 4 score | Week 8 5 score | Week 12 0 score | Week 12 1 score | Week 12 2 score | Week 12 3 score | Week 12 4 score | Week 12 5 score | Week 16 0 score | Week 16 1 score | Week 16 2 score | Week 16 3 score | Week 16 4 score | Week 16 5 score | |
Placebo - TP 1 - CLP Cohort | 0 | 0 | 0 | 3 | 6 | 3 | 0 | 0 | 1 | 3 | 5 | 3 | 0 | 0 | 0 | 3 | 5 | 3 | 0 | 1 | 1 | 2 | 4 | 3 | 0 | 1 | 2 | 0 | 7 | 2 | 0 | 2 | 3 | 3 | 4 | 0 |
The Physician Assessment of Surface Area of Disease (PSAD) evaluates the extent of cutaneous lesions estimated by investigator or qualified designee. Assessment scores range from 0-5, with lower scores corresponding to lower percentages of surface area with disease: 0=clear, 1=<2%, 2=2-9%, 3=10-29%, 4=30-50%, 5=>50% of total body surface (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Baseline 0 Score | Baseline 1 score | Baseline 2 score | Baseline 3 score | Baseline 4 score | Baseline 5 score | Week 2 0 score | Week 2 1 score | Week 2 2 score | Week 2 3 score | Week 2 4 score | Week 2 5 score | Week 4 0 score | Week 4 1 score | Week 4 2 score | Week 4 3 score | Week 4 4 score | Week 4 5 score | Week 8 0 score | Week 8 1 score | Week 8 2 score | Week 8 3 score | Week 8 4 score | Week 8 5 score | Week 12 0 score | Week 12 1 score | Week 12 2 score | Week 12 3 score | Week 12 4 score | Week 12 5 score | Week 16 0 score | Week 16 1 score | Week 16 2 score | Week 16 3 score | Week 16 4 score | Week 16 5 score | Week 20 0 score | Week 20 1 score | Week 20 2 score | Week 20 3 score | Week 20 4 score | Week 20 5 score | Week 24 0 score | Week 24 1 score | Week 24 2 score | Week 24 3 score | Week 24 4 score | Week 24 5 score | Week 28 0 score | Week 28 1 score | Week 28 2 score | Week 28 3 score | Week 28 4 score | Week 28 5 score | Week 32 0 score | Week 32 1 score | Week 32 2 score | Week 32 3 score | Week 32 4 score | Week 32 5 score | |
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | 0 | 3 | 6 | 6 | 5 | 5 | 0 | 6 | 5 | 9 | 3 | 2 | 0 | 3 | 8 | 8 | 3 | 2 | 0 | 7 | 5 | 7 | 4 | 2 | 0 | 6 | 7 | 7 | 3 | 2 | 0 | 4 | 12 | 5 | 2 | 2 | 0 | 6 | 12 | 3 | 1 | 2 | 1 | 8 | 10 | 1 | 2 | 3 | 0 | 6 | 11 | 1 | 3 | 2 | 2 | 5 | 10 | 3 | 1 | 3 |
"The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||
---|---|---|---|---|---|
Baseline n=25,12,0 | Week 4 n=24,11,0 | Week 8 n=25,11,0 | Week 12 n=25,12,0 | Week 16 n=25,12,10 | |
Placebo - TP 1 - CLP Cohort | 0 | 0 | 0 | 1 | 2 |
"The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||
---|---|---|---|---|---|
Week 16 n=25,12,10 | Week 20 n=24,0,10 | Week 24 n=25,0,10 | Week 28 n=23,0,10 | Week 32 n=25,0,9 | |
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort | 2 | 1 | 1 | 1 | 1 |
"The Dermatology Life Quality Index (DLQI) is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline n=25,12,0 | Week 4 n=24,11,0 | Week 8 n=25,11,0 | Week 12 n=25,12,0 | Week 16 n=25,12,10 | Week 20 n=24,0,10 | Week 24 n=25,0,10 | Week 28 n=23,0,10 | Week 32 n=25,0,9 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | 0 | 2 | 2 | 3 | 3 | 3 | 4 | 3 | 2 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||
---|---|---|---|---|---|
Baseline n=24,13,0 | Week 4 n=24,13,0 | Week 8 n=24,13,0 | Week 12 n=24,13,0 | Week 16 n=24,13,13 | |
Placebo - TP 1 - LPP Cohort | 0 | 1 | 1 | 2 | 1 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||
---|---|---|---|---|---|
Week 16 n=24,13,13 | Week 20 n=24,0,13 | Week 24 n=23,0,13 | Week 28 n=24,0,13 | Week 32 n=24,0,11 | |
Placebo to AIN457 300 mg Q2W TP 2 - LPP Cohort | 1 | 3 | 3 | 2 | 3 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline n=24,13,0 | Week 4 n=24,13,0 | Week 8 n=24,13,0 | Week 12 n=24,13,0 | Week 16 n=24,13,13 | Week 20 n=24,0,13 | Week 24 n=23,0,13 | Week 28 n=24,0,13 | Week 32 n=24,0,11 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | 0 | 3 | 3 | 2 | 2 | 4 | 2 | 2 | 1 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||
---|---|---|---|---|---|
Baseline n=24,13,0 | Week 4 n=24,13,0 | Week 8 n=24,13,0 | Week 12 n=24,13,0 | Week 16 n=24,13,11 | |
Placebo - TP 1 - MLP Cohort | 0 | 1 | 1 | 2 | 3 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||
---|---|---|---|---|---|
Week 16 n=24,13,11 | Week 20 n=24,0,11 | Week 24 n=24,0,10 | Week 28 n=23,0,11 | Week 32 n=23,0,10 | |
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 2 | 2 | 3 | 2 | 2 |
"The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts (Finlay and Khan 1994). The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. The recall period is the last week, and the instrument requires 1 to 2 minutes for completion. Each item has four response categories ranging from 0 (not at all) to 3 (very much). Not relevant is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment." (NCT04300296)
Timeframe: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline n=24,13,0 | Week 4 n=24,13,0 | Week 8 n=24,13,0 | Week 12 n=24,13,0 | Week 16 n=24,13,11 | Week 20 n=24,0,11 | Week 24 n=24,0,10 | Week 28 n=23,0,11 | Week 32 n=23,0,10 | |
AIN457 300 mg Q4W - TP 1 and TP 2- MLP Cohort | 0 | 2 | 4 | 4 | 5 | 7 | 7 | 3 | 4 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 2 IGA <=2 n=25,12,0 | Week 2 IGA improvement >=2 n=25,12,0 | Week 2 IGA 0/1 n=25,12,0 | Week 4 IGA <=2 n=24,11,0 | Week 4 IGA improvement. >=2 n=24,11,0 | Week 4 IGA 0/1 n=24,11,0 | Week 8 IGA <=2 n=25,11,0 | Week 8 IGA improvement. >=2 n=25,11,0 | Week 8 IGA 0/1 n=25,11,0 | Week 12 IGA <=2 n=25,12,0 | Week 12 IGA improvement. >=2 n=25,12,0 | Week 12 IGA 0/1 n=25,12,0 | Week16 IGA <=2 n=25,12,10 | Week 16 IGA improvement. >=2 n=25,12,10 | Week 16 IGA 0/1 n=25,12,10 | |
Placebo - TP 1 - CLP Cohort | 1 | 0 | 0 | 2 | 0 | 0 | 3 | 1 | 1 | 4 | 2 | 1 | 7 | 3 | 2 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week16 IGA <=2 n=25,12,10 | Week 16 IGA improvement. >=2 n=25,12,10 | Week 16 IGA 0/1 n=25,12,10 | Week 20 IGA <=2 n=24,0,10 | Week 20 IGA improvement. >=2 n=24,0,10 | Week 20 IGA 0/1 n=24,0,10 | Week 24 IGA <=2 n=25,0,10 | Week 24 IGA improvement. >=2 n=25,0,10 | Week 24 IGA 0/1 n=25,0,10 | Week 28 IGA <=2 n=23,0,10 | Week 28 IGA improvement. >=2 n=23,0,10 | Week 28 IGA 0/1 n=23,0,10 | Week 32 IGA <=2 n=24,0,9 | Week 32 IGA improvement. >=2 n=24,0,9 | Week 32 IGA 0/1 n=24,0,9 | |
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort | 5 | 1 | 0 | 1 | 1 | 1 | 3 | 2 | 1 | 4 | 1 | 1 | 2 | 2 | 1 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 2 IGA <=2 n=25,12,0 | Week 2 IGA improvement >=2 n=25,12,0 | Week 2 IGA 0/1 n=25,12,0 | Week 4 IGA <=2 n=24,11,0 | Week 4 IGA improvement. >=2 n=24,11,0 | Week 4 IGA 0/1 n=24,11,0 | Week 8 IGA <=2 n=25,11,0 | Week 8 IGA improvement. >=2 n=25,11,0 | Week 8 IGA 0/1 n=25,11,0 | Week 12 IGA <=2 n=25,12,0 | Week 12 IGA improvement. >=2 n=25,12,0 | Week 12 IGA 0/1 n=25,12,0 | Week16 IGA <=2 n=25,12,10 | Week 16 IGA improvement. >=2 n=25,12,10 | Week 16 IGA 0/1 n=25,12,10 | Week 20 IGA <=2 n=24,0,10 | Week 20 IGA improvement. >=2 n=24,0,10 | Week 20 IGA 0/1 n=24,0,10 | Week 24 IGA <=2 n=25,0,10 | Week 24 IGA improvement. >=2 n=25,0,10 | Week 24 IGA 0/1 n=25,0,10 | Week 28 IGA <=2 n=23,0,10 | Week 28 IGA improvement. >=2 n=23,0,10 | Week 28 IGA 0/1 n=23,0,10 | Week 32 IGA <=2 n=24,0,9 | Week 32 IGA improvement. >=2 n=24,0,9 | Week 32 IGA 0/1 n=24,0,9 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | 5 | 2 | 2 | 9 | 3 | 2 | 10 | 4 | 3 | 10 | 3 | 4 | 11 | 4 | 4 | 11 | 5 | 5 | 14 | 10 | 10 | 12 | 7 | 6 | 9 | 7 | 6 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 2 IGA <=2 n=24,13,0 | Week 2 IGA improvement >=2 n=24,13,0 | Week 2 IGA 0/1 n=24,13,0 | Week 4 IGA <=2 n=24,13,0 | Week 4 IGA improvement. >=2 n=24,13,0 | Week 4 IGA 0/1 n=24,13,0 | Week 8 IGA <=2 n=24,13,0 | Week 8 IGA improvement. >=2 n=24,13,0 | Week 8 IGA 0/1 n=24,13,0 | Week 12 IGA <=2 n=24,13,0 | Week 12 IGA improvement. >=2 n=24,13,0 | Week 12 IGA 0/1 n=24,13,0 | Week16 IGA <=2 n=24,13,13 | Week 16 IGA improvement. >=2 n=24,13,13 | Week 16 IGA 0/1 n=24,13,13 | |
Placebo - TP 1 - LPP Cohort | 1 | 0 | 0 | 2 | 1 | 1 | 3 | 1 | 1 | 4 | 2 | 2 | 4 | 0 | 0 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week16 IGA <=2 n=24,13,13 | Week 16 IGA improvement. >=2 n=24,13,13 | Week 16 IGA 0/1 n=24,13,13 | Week 20 IGA <=2 n=24,0,13 | Week 20 IGA improvement. >=2 n=24,0,13 | Week 20 IGA 0/1 n=24,0,13 | Week 24 IGA <=2 n=23,0,13 | Week 24 IGA improvement. >=2 n=23,0,13 | Week 24 IGA 0/1 n=23,0,13 | Week 28 IGA <=2 n=24,0,13 | Week 28 IGA improvement. >=2 n=24,0,13 | Week 28 IGA 0/1 n=24,0,13 | Week 32 IGA <=2 n==24,0,11 | Week 32 IGA improvement. >=2 n==24,0,11 | Week 32 IGA 0/1 n==24,0,11 | |
Placebo to AIN457 300 mg Q2W - TP 2- LPP Cohort | 4 | 0 | 0 | 6 | 1 | 0 | 8 | 3 | 2 | 9 | 4 | 3 | 7 | 5 | 4 |
Number of subjects with IGA of 2 or lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 2 IGA <=2 n=24,13,0 | Week 2 IGA improvement >=2 n=24,13,0 | Week 2 IGA 0/1 n=24,13,0 | Week 4 IGA <=2 n=24,13,0 | Week 4 IGA improvement. >=2 n=24,13,0 | Week 4 IGA 0/1 n=24,13,0 | Week 8 IGA <=2 n=24,13,0 | Week 8 IGA improvement. >=2 n=24,13,0 | Week 8 IGA 0/1 n=24,13,0 | Week 12 IGA <=2 n=24,13,0 | Week 12 IGA improvement. >=2 n=24,13,0 | Week 12 IGA 0/1 n=24,13,0 | Week16 IGA <=2 n=24,13,13 | Week 16 IGA improvement. >=2 n=24,13,13 | Week 16 IGA 0/1 n=24,13,13 | Week 20 IGA <=2 n=24,0,13 | Week 20 IGA improvement. >=2 n=24,0,13 | Week 20 IGA 0/1 n=24,0,13 | Week 24 IGA <=2 n=23,0,13 | Week 24 IGA improvement. >=2 n=23,0,13 | Week 24 IGA 0/1 n=23,0,13 | Week 28 IGA <=2 n=24,0,13 | Week 28 IGA improvement. >=2 n=24,0,13 | Week 28 IGA 0/1 n=24,0,13 | Week 32 IGA <=2 n==24,0,11 | Week 32 IGA improvement. >=2 n==24,0,11 | Week 32 IGA 0/1 n==24,0,11 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | 4 | 1 | 1 | 9 | 2 | 2 | 8 | 3 | 3 | 8 | 3 | 2 | 9 | 3 | 2 | 10 | 6 | 4 | 10 | 7 | 6 | 10 | 6 | 5 | 11 | 5 | 4 |
Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 2 IGA <=2 n=24,12,0 | Week 2 IGA improvement >=2 n=24,12,0 | Week 2 IGA 0/1 n=24,12,0 | Week 4 IGA <=2 n=24,13,0 | Week 4 IGA improvement. >=2 n=24,13,0 | Week 4 IGA 0/1 n=24,13,0 | Week 8 IGA <=2 n=24,13,0 | Week 8 IGA improvement. >=2 n=24,13,0 | Week 8 IGA 0/1 n=24,13,0 | Week 12 IGA <=2 n=24,13,0 | Week 12 IGA improvement. >=2 n=24,13,0 | Week 12 IGA 0/1 n=24,13,0 | Week16 IGA <=2 n=24,13,11 | Week 16 IGA improvement. >=2 n=24,13,11 | Week 16 IGA 0/1 n=24,13,11 | |
Placebo - TP 1 - MLP Cohort | 3 | 1 | 1 | 2 | 1 | 1 | 3 | 2 | 1 | 4 | 4 | 2 | 3 | 3 | 2 |
Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week16 IGA <=2 n=24,13,11 | Week 16 IGA improvement. >=2 n=24,13,11 | Week 16 IGA 0/1 n=24,13,11 | Week 20 IGA <=2 n=24,0,11 | Week 20 IGA improvement. >=2 n=24,0,11 | Week 20 IGA 0/1 n=24,0,11 | Week 24 IGA <=2 n=24,0,10 | Week 24 IGA improvement. >=2 n=24,0,10 | Week 24 IGA 0/1 n=24,0,10 | Week 28 IGA <=2 n=23,0,11 | Week 28 IGA improvement. >=2 n=23,0,11 | Week 28 IGA 0/1 n=23,0,11 | Week 32 IGA <=2 n=23,0,10 | Week 32 IGA improvement. >=2 n=23,0,10 | Week 32 IGA 0/1 n=23,0,10 | |
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 1 | 1 | 0 | 3 | 2 | 1 | 4 | 2 | 0 | 4 | 3 | 0 | 2 | 1 | 0 |
Number of subjects with IGA of 2 of lower, improvement in the IGA score of at least 2 points, or IGA score of 0/1. IGA is measured on a scale from 0-4 with 0=Clear, 1=minimal, 2=mild, 3=moderate, and 4=severe with 0 being best score and 4 being worst score. (NCT04300296)
Timeframe: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, and 32
Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Week 2 IGA <=2 n=24,12,0 | Week 2 IGA improvement >=2 n=24,12,0 | Week 2 IGA 0/1 n=24,12,0 | Week 4 IGA <=2 n=24,13,0 | Week 4 IGA improvement. >=2 n=24,13,0 | Week 4 IGA 0/1 n=24,13,0 | Week 8 IGA <=2 n=24,13,0 | Week 8 IGA improvement. >=2 n=24,13,0 | Week 8 IGA 0/1 n=24,13,0 | Week 12 IGA <=2 n=24,13,0 | Week 12 IGA improvement. >=2 n=24,13,0 | Week 12 IGA 0/1 n=24,13,0 | Week16 IGA <=2 n=24,13,11 | Week 16 IGA improvement. >=2 n=24,13,11 | Week 16 IGA 0/1 n=24,13,11 | Week 20 IGA <=2 n=24,0,11 | Week 20 IGA improvement. >=2 n=24,0,11 | Week 20 IGA 0/1 n=24,0,11 | Week 24 IGA <=2 n=24,0,10 | Week 24 IGA improvement. >=2 n=24,0,10 | Week 24 IGA 0/1 n=24,0,10 | Week 28 IGA <=2 n=23,0,11 | Week 28 IGA improvement. >=2 n=23,0,11 | Week 28 IGA 0/1 n=23,0,11 | Week 32 IGA <=2 n=23,0,10 | Week 32 IGA improvement. >=2 n=23,0,10 | Week 32 IGA 0/1 n=23,0,10 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | 5 | 1 | 1 | 4 | 1 | 1 | 5 | 0 | 0 | 5 | 5 | 4 | 9 | 5 | 4 | 10 | 5 | 5 | 10 | 3 | 3 | 7 | 1 | 1 | 9 | 2 | 2 |
The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | |
---|---|---|
Baseline n=24,13,13 | Week 16 n=24,13,13 | |
Placebo - TP 1 - LPP Cohort | 5.95 | -2.24 |
The LPPAI assesses symptoms (pruritus, pain, burning), signs (erythema, perifollicular erythema and scale), a measure of activity (pull test) and extension of disease. These subjective and objective measures are assigned numeric values to establish a disease activity score. The total score ranges from 0 to 10, with higher scores corresponding to higher disease activity (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline n=24,13,13 | Week 16 n=24,13,13 | Week 32 n=24,0,13 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | 5.92 | -1.44 | -2.44 |
Placebo to AIN457 300 mg Q2W TP 2 - Lpp Cohort | 5.95 | -2.24 | -3.20 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline - Question 1 | Week 16 Severity of itch during past 24 hours n=25,12,10 | Baseline- Question 2 | Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10 | Baseline- Question 3 | Week 16 How bothered by Itch during past 24 hours n=25,12,10 | |
Placebo - TP 1 - CLP Cohort | 5.7 | -2.3 | 6.3 | -2.7 | 6.1 | -2.7 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline - Question 1 | Week 16 Severity of itch during past 24 hours n=25,12,10 | Week 32 Severity of itch during past 24 hours n=25,0,9 | Baseline- Question 2 | Week 16 How severe was itch at worst moment during past 24 hours n=25,12,10 | Week 32 How severe was itch at worst moment during past 24 hours n=25,0,9 | Baseline- Question 3 | Week 16 How bothered by Itch during past 24 hours n=25,12,10 | Week 32 How bothered by Itch during past 24 hours n=25,0,9 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | 5.1 | -0.8 | -1.5 | 5.6 | -0.9 | -1.3 | 4.8 | -1.0 | -1.1 |
Placebo to AIN457 300 mg Q2W TP 2 - CLP Cohort | 5.8 | -2.0 | -1.1 | 5.9 | -1.9 | -1.2 | 6.1 | -2.4 | -1.2 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline - Question 1 n=24,13,13 | Week 16 Severity of itch during past 24 hours n=24,13,11 | Baseline - Question 2 n=24,13,13 | Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by Itch during past 24 hours n=24,13,13 | |
Placebo - TP 1 - LPP Cohort | 3.8 | -1.1 | 4.2 | -1.3 | 3.2 | -1.2 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline - Question 1 n=24,13,13 | Week 16 Severity of itch during past 24 hours n=24,13,11 | Week 32 Severity of itch during past 24 hours n=24,0,11 | Baseline - Question 2 n=24,13,13 | Week 16 How severe was itch at worst moment during past 24 hours n=24,13,13 | Week 32 How severe was itch at worst moment during past 24 hours n=24,0,11 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by Itch during past 24 hours n=24,13,13 | Week 32 How bothered by Itch during past 24 hours n=24,0,11 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | 4.5 | -0.5 | -1.6 | 5.1 | -0.7 | -1.8 | 4.0 | -0.4 | -1.7 |
Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort | 3.8 | -1.1 | -2.4 | 4.1 | -1.3 | -2.6 | 3.2 | -1.2 | -2.2 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline - Question 1 n=23,13,11 | Week 16 Severity of itch during past 24 hours n=23,13,11 | Baseline - Question 2 n=23,13,11 | Week 16 How severe was itch at worst moment during past 24 hours n=23,13,11 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by Itch during past 24 hours n=23,13,11 | |
Placebo - TP 1 - MLP Cohort | 3.8 | -0.2 | 3.6 | 0.4 | 4.0 | 0.1 |
"Itch is assessed with the following questions: • Overall, how severe was your lichen planus-related itching during the past 24 hours? • How severe was your lichen planus-related itching at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related itching during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no itch and 10 meaning the worst itch imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline - Question 1 n=23,13,11 | Week 16 Severity of itch during past 24 hours n=23,13,11 | Week 32 Severity of itch during past 24 hours n=22,0,10 | Baseline - Question 2 n=23,13,11 | Week 16 How severe was itch at worst moment during past 24 hours n=23,13,11 | Week 32 How severe was itch at worst moment during past 24 hours n=22,0,10 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by Itch during past 24 hours n=23,13,11 | Week 32 How bothered by Itch during past 24 hours n=22,0,10 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | 2.5 | 0.3 | 0.1 | 2.4 | 0.8 | 0.3 | 3.4 | -0.5 | -0.2 |
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 4.3 | -0.3 | -0.4 | 4.1 | 0.4 | 0.4 | 4.5 | 0.0 | -0.4 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline - Question 1 n=25,12,10 | Week 16 Severity of pain during past 24 hours n=25,12,10 | Baseline - Question 2 n=25,12,10 | Week 16 How severe was pain at worst moment during past 24 hours n=25,12,10 | Baseline - Question 3 n=25,12,10 | Week 16 How bothered by pain during past 24 hour n=25,12,10 | |
Placebo - TP 1 - CLP Cohort | 3.4 | -0.8 | 3.9 | -1.2 | 3.7 | -0.6 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline - Question 1 n=25,12,10 | Week 16 Severity of pain during past 24 hours n=25,12,10 | Week 32 Severity of pain during past 24 hours n=25,0,9 | Baseline - Question 2 n=25,12,10 | Week 16 How severe was pain at worst moment during past 24 hours n=25,12,10 | Week 32 How severe was pain at worst moment during past 24 hours n=25,0,9 | Baseline - Question 3 n=25,12,10 | Week 16 How bothered by pain during past 24 hour n=25,12,10 | Week 32 How bothered by pain during past 24 hours n=25, 0,9 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - CLP Cohort | 1.09 | 0.2 | -0.3 | 2.2 | 0.1 | -0.4 | 2.1 | 0.1 | -0.2 |
Placebo to AIN457 300 mg Q2W - TP 2 - CLP Cohort | 3.5 | -0.8 | -0.3 | 3.9 | -1.0 | -0.4 | 3.8 | 0.5 | -0.3 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline - Question 1 n=24,13,12 | Week 16 Severity of pain during past 24 hours n=24,13,12 | Baseline - Question 2 24,13,12 | Week 16 How severe was pain at worst moment during past 24 hours n=24,13,12 | Baseline - Question 3 n=24,13,12 | Week 16 How bothered by pain during past 24 hour n=24,13,12 | |
Placebo - TP 1 - LPP Cohort | 2.0 | -0.5 | 2.5 | -0.9 | 2.4 | -1.1 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline - Question 1 n=24,13,12 | Week 16 Severity of pain during past 24 hours n=24,13,12 | Week 32 Severity of pain during past 24 hours n=24,0,11 | Baseline - Question 2 24,13,12 | Week 16 How severe was pain at worst moment during past 24 hours n=24,13,12 | Week 32 How severe was pain at worst moment during past 24 hours n=24,0,11 | Baseline - Question 3 n=24,13,12 | Week 16 How bothered by pain during past 24 hour n=24,13,12 | Week 32 How bothered by pain during past 24 hours n=24,0,11 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - LPP Cohort | 2.5 | 0.3 | -0.6 | 2.8 | 0.2 | -0.8 | 2.7 | 0.0 | -0.8 |
Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort | 2.0 | -0.5 | -1.5 | 2.5 | -0.9 | -2.0 | 2.4 | -1.1 | -1.9 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | |||||
---|---|---|---|---|---|---|
Baseline - Question 1 n=24,13,11 | Week 16 Severity of pain during past 24 hours n=24,13,11 | Baseline - Question 2 n=24,13,11 | Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by pain during past 24 hour n=24,13,11 | |
Placebo - TP 1 - MLP Cohort | 5.9 | -0.1 | 6.4 | -0.3 | 6.5 | -0.3 |
"Pain is assessed with the following questions: • Overall, how severe was your lichen planus-related pain during the past 24 hours? • How severe was your lichen planus-related pain at the worst moment during the past 24 hours? • Overall, how bothered were you by your lichen planus-related pain during the past 24 hours? Answers are given on a numeric rating scale (NRS) from 0 to 10, with 0 meaning no pain and 10 meaning the worst pain imaginable." (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Baseline - Question 1 n=24,13,11 | Week 16 Severity of pain during past 24 hours n=24,13,11 | Week 32 Severity of pain during past 24 hours n=23,0,10 | Baseline - Question 2 n=24,13,11 | Week 16 How severe was pain at worst moment during past 24 hours n=24,13,11 | Week 32 How severe was pain at worst moment during past 24 hours n=23,0,10 | Baseline - Question 3 n=24,13,11 | Week 16 How bothered by pain during past 24 hour n=24,13,11 | Week 32 How bothered by pain during past 24 hours n=23,0,10 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | 5.1 | -0.5 | -0.3 | 5.4 | -0.5 | -0.3 | 5.5 | -0.8 | -0.5 |
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 6.3 | 0.0 | -0.6 | 6.7 | -0.2 | -0.5 | 6.8 | -0.1 | -0.9 |
Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | |
---|---|---|
Baseline n=24,13,12 | Week 16 n=24,13,12 | |
Placebo - TP 1 - LPP Cohort | 54.01 | -6.94 |
Scalpdex is a self-administered, health-related quality of life instrument originally developed for scalp dermatitis. This survey includes 23 items, each item scored on a scale of 0-100, where 0=never, 25=rarely, 50=sometimes, 75=often and 100=all the time. The 23 items pertain to 3 domains: symptom, emotions and functioning. Subjects were asked to score themselves on how true each of the 23 statements has been for them over the past four weeks. the total score is the average of the scores of the 23 items. A higher total score indicated a higher impairment in quality of life. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline n=24,13,12 | Week 16 n=24,13,12 | Week 32 n=24,0,11 | |
AIN457 300 mg Q4W - TP 1 and TP 2 -LPP Cohort | 55.75 | 1.86 | -4.26 |
Placebo to AIN457 300 mg Q2W - TP 2 - LPP Cohort | 54.01 | -6.94 | -14.43 |
OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | |
---|---|---|
Baseline n=21,12,10 | Week 16 n=21,12,10 | |
Placebo - TP 1 - MLP Cohort | 13.4 | 0.8 |
OLPSSM is a self-administered assessment of the symptom experience of subjects with oral LP in clinical studies. It includes 7 triggers contributing to soreness of oral lichen planus: Brushing teeth, eating food, drinking liquids, smiling, breathing through mouth, talking and touching. These 7 items contributed equally to a total OLP symptom severity score, ranging from 0 to 28, with higher scores indicating worse severity. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline n=21,12,10 | Week 16 n=21,12,10 | Week 32 n=20,0,9 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | 11.0 | -1.0 | -1.8 |
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 13.9 | -0.4 | -0.7 |
REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | |
---|---|---|
Baseline n=21,12,10 | Week 16 n=21,12,10 | |
Placebo - TP 1 - MLP Cohort | 25.29 | -5.79 |
REU measured disease severity based on 3 dimensions: reticulation, erythema and ulceration for all subjects in the MLP cohort who had an oral presentation of the disease. The total score ranged from 0-115 with higher values corresponding to higher activity of the disease. (NCT04300296)
Timeframe: Baseline, Week 16 and Week 32
Intervention | scores on a scale (Mean) | ||
---|---|---|---|
Baseline n=21,12,10 | Week 16 n=21,12,10 | Week 32 n=20,0,9 | |
AIN457 300 mg Q4W - TP 1 and TP 2 - MLP Cohort | 21.31 | -4.83 | -6.08 |
Placebo to AIN457 300 mg Q2W TP 2 - MLP Cohort | 26.95 | -4.10 | -2.17 |
Average number of steps walked per day from baseline to the end of each treatment. (NCT02960997)
Timeframe: 12 weeks
Intervention | steps (Mean) |
---|---|
Sirolimus | 6624 |
Placebo | 7130 |
Trough measurements were taken prior to topical sirolimus administration at the week 12 study visit. (NCT02960997)
Timeframe: Week 12
Intervention | ng/mL (Mean) |
---|---|
Sirolimus | NA |
The 5-D Pruritus Scale is a 1-page, 5-question tool used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; participants were to rate their symptoms over the preceding 2-week period on a 1 to 5 scale, with 5 being the most affected. After the summation of individual score, the total score ranges from 5 (least affected) to 25 (most affected). Data are reported per intervention. (NCT02960997)
Timeframe: Week 0 and week 12 of the respective treatment period
Intervention | score on a scale (Mean) | |
---|---|---|
Week 0 | Week 12 | |
Placebo | 11.5 | 11.8 |
Sirolimus | 12.8 | 12.5 |
Quality of Life-Epidermolysis Bullosa (QOLEB) Questionnaire specifically designed for people with EB. The QOLEB can be used to identify everyday life occurrences negatively affected by EB. It assesses change in quality of life over time, an important measure when assessing the success of new treatments for EB. Scores from 0 to 51, with higher scores indicate greater impact of EB on quality of life. Data are reported per intervention. (NCT02960997)
Timeframe: Week 0 and week 12 of the respective treatment period
Intervention | score on a scale (Mean) | |
---|---|---|
Week 0 | Week 12 | |
Placebo | 6.6 | 13.3 |
Sirolimus | 14.1 | 14.5 |
The EBDASI is a validated scoring system that objectively quantifies the severity of EB affecting the entire body. It has been designed to evaluate the response to new therapies for the treatment of EB. Scores range from 0 (absent of EB) to 10 (entire area involved). Data are reported per intervention. (NCT02960997)
Timeframe: Week 0 and week 12 of the respective treatment period
Intervention | score on a scale (Mean) | |
---|---|---|
Week 0 | Week 12 | |
Placebo | 3.5 | 2.5 |
Sirolimus | 2.6 | 2.9 |
Foot function was assessed utilizing the validated Foot Health Status Questionnaire (FHSQ). Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported per intervention. (NCT02960997)
Timeframe: Week 0 and week 12 of the respective treatment period
Intervention | score on a scale (Mean) | |
---|---|---|
Week 0 | Week 12 | |
Placebo | 49.3 | 56.3 |
Sirolimus | 61.7 | 60.2 |
Physical Activity was assessed utilizing the validated Foot Health Status Questionnaire (FHSQ). Low Score (0) means severely limited in performing a broad range of physical activities. High Score (100) means can perform all desired physical activities. Data are reported per intervention. (NCT02960997)
Timeframe: Week 0 and week 12 of the respective treatment period
Intervention | score on a scale (Mean) | |
---|---|---|
Week 0 | Week 12 | |
Placebo | 54.2 | 61.8 |
Sirolimus | 69.4 | 70.8 |
43 reviews available for salicylic acid and Cicatrization
Article | Year |
---|---|
Treatment of Alopecia in Children.
Topics: Alopecia; Biopsy; Child; Cicatrix; Hair; Humans; Scalp | 2022 |
Natural results of scalp micropigmentation: A review.
Topics: Alopecia; Cicatrix; Humans; Scalp; Skin Transplantation | 2022 |
EROSIVE PUSTULAR DERMATOSIS OF THE SCALP (EPDS) - A CASE SERIES AND SHORT REVIEW.
Topics: Aged; Alopecia; Cicatrix; Communicable Diseases; Humans; Scalp; Skin | 2023 |
Scarring Alopecia.
Topics: Alopecia; Cicatrix; Hair; Humans; Lupus Erythematosus, Discoid; Scalp | 2023 |
The role of the scalp biopsy in the evaluation of alopecia.
Topics: Alopecia; Biopsy; Cicatrix; Hair; Humans; Scalp | 2023 |
PPAR-γ signalling as a key mediator of human hair follicle physiology and pathology.
Topics: Alopecia; Animals; Cicatrix; Epithelial-Mesenchymal Transition; Hair; Hair Diseases; Hair Follicle; | 2020 |
[Alopecia-keep a cool head].
Topics: Alopecia; Biopsy; Cicatrix; Humans; Scalp | 2020 |
A proposed mechanism for central centrifugal cicatricial alopecia.
Topics: Alopecia; Cicatrix; Fibrosis; Humans; Kidney; Kidney Diseases; Lichen Planus; PPAR gamma; Scalp; Scl | 2020 |
Morphea «En Coup De Sabre» at the Site of Healed Herpes Zoster Ophthalmicus.
Topics: Adult; Alopecia; Cicatrix; Facial Dermatoses; Female; Forehead; Herpes Zoster Ophthalmicus; Humans; | 2019 |
Nonshaven Follicular Unit Extraction: Personal Experience.
Topics: Adult; Alopecia; Cicatrix; Esthetics; Female; Graft Survival; Hair; Hair Follicle; Humans; Male; Mid | 2019 |
The Applications of Medical Tattooing in the Head and Neck Region.
Topics: Alopecia; Cicatrix; Humans; Quality of Life; Scalp; Tattooing | 2019 |
Graham-Little-Piccardi-Lasseur syndrome: case report and review of the syndrome in men.
Topics: Abnormalities, Multiple; Adult; Alopecia; Axilla; Cicatrix; Darier Disease; Eyebrows; Humans; Lichen | 2014 |
Primary cicatricial alopecia: diagnosis and treatment.
Topics: Alopecia; Biopsy; Cicatrix; Diagnosis, Differential; Disease Management; Humans; Scalp | 2013 |
Graft harvesting and management of the donor site.
Topics: Alopecia; Cicatrix; Cosmetic Techniques; Dermatologic Surgical Procedures; Hair; Hair Follicle; Huma | 2013 |
Hair loss in autoimmune systemic diseases.
Topics: Alopecia; Alopecia Areata; Autoimmune Diseases; Cicatrix; Connective Tissue Diseases; Hair Diseases; | 2014 |
Trichoscopy: an update.
Topics: Alopecia; Black People; Cicatrix; Dermoscopy; Hair; Hair Diseases; Humans; Lice Infestations; Refere | 2014 |
Complications in tissue expansion: an updated retrospective analysis of risk factors.
Topics: Adolescent; Adult; Child; Cicatrix; Extremities; Face; Female; Hand; Humans; Male; Middle Aged; Neck | 2014 |
Central centrifugal cicatricial alopecia: what has been achieved, current clues for future research.
Topics: Alopecia Areata; Black or African American; Cicatrix; Female; Humans; Prevalence; Risk Factors; Scal | 2014 |
Follicular and scarring disorders in skin of color: presentation and management.
Topics: Alopecia; Cicatrix; Hair Follicle; Humans; Quality of Life; Racial Groups; Scalp; Skin Diseases; Ski | 2014 |
Scalp dermoscopy or trichoscopy.
Topics: Alopecia; Alopecia Areata; Cicatrix; Dermoscopy; Hair Diseases; Humans; Lupus Erythematosus, Discoid | 2015 |
Primary scarring alopecias.
Topics: Acne Keloid; Alopecia; Cellulitis; Cicatrix; Fibrosis; Folliculitis; Humans; Lichen Planus; Lupus Er | 2015 |
Diagnosis and management of hair loss in children.
Topics: Age Factors; Child; Cicatrix; Dermoscopy; Diagnosis, Differential; Hair Diseases; Humans; Medical Hi | 2016 |
Diagnostic value of horizontal versus vertical sections for scarring and non-scarring alopecia: a systematic review and meta-analysis.
Topics: Alopecia; Biopsy; Cicatrix; Humans; Microtomy; Scalp; Skin | 2016 |
Primary scalp alopecia: new histopathological tools, new concepts and a practical guide to diagnosis.
Topics: Alopecia; Cicatrix; Female; Humans; Male; Scalp | 2017 |
Treatment of Scalp Scars.
Topics: Cicatrix; Humans; Plastic Surgery Procedures; Scalp; Skin Transplantation; Surgical Flaps; Tissue Ex | 2017 |
Hair transplantation for men.
Topics: Alopecia; Cicatrix; Cosmetic Techniques; Finasteride; Hair; Hair Follicle; Humans; Low-Level Light T | 2008 |
Iatrogenic skin injury in the neonatal intensive care unit.
Topics: Burns; Cicatrix; Humans; Iatrogenic Disease; Infant, Extremely Low Birth Weight; Infant, Newborn; In | 2011 |
Iron deficiency and diffuse nonscarring scalp alopecia in women: more pieces to the puzzle.
Topics: Alopecia; Anemia, Iron-Deficiency; Animals; Cicatrix; Female; Humans; Iron; Scalp | 2010 |
The coronal scalp flap: surgical technique.
Topics: Blood Loss, Surgical; Cicatrix; Electrocoagulation; Facial Nerve Injuries; Humans; Plastic Surgery P | 2010 |
Burn reconstruction.
Topics: Alopecia; Burns; Cicatrix; Contracture; Face; Humans; Lower Extremity; Mammaplasty; Perineum; Pigmen | 2011 |
Sarcoidosis-induced alopecia.
Topics: Alopecia; Black or African American; Cicatrix; Female; Humans; Male; Middle Aged; Sarcoidosis; Scalp | 2012 |
Histopathology of scarring and nonscarring hair loss.
Topics: Alopecia; Biopsy; Cicatrix; Diagnosis, Differential; Hair Diseases; Hair Follicle; Humans; Microtomy | 2013 |
Hair sparing techniques and scalp flap design.
Topics: Cicatrix; Hair; Humans; Plastic Surgery Procedures; Scalp; Skull; Surgical Flaps | 2002 |
Intricacies of the single-scar technique for donor harvesting in hair transplantation surgery.
Topics: Cicatrix; Hair Follicle; Humans; Plastic Surgery Procedures; Scalp | 2004 |
Cicatricial eyebrow reconstruction with a dense-packing one- to two-hair grafting technique.
Topics: Adolescent; Adult; Burns; Burns, Chemical; Child; Cicatrix; Esthetics; Eyebrows; Facial Injuries; Fe | 2004 |
Review of scalp alopecia due to a clinically unapparent or minimally apparent neoplasm (SACUMAN).
Topics: Alopecia; Breast Neoplasms; Carcinoma, Basal Cell; Cicatrix; Hemangiosarcoma; Humans; Keloid; Lympho | 2006 |
Minimal scars for scalp surgery.
Topics: Cicatrix; Humans; Postoperative Complications; Scalp; Skin; Suture Techniques; Wound Healing | 2007 |
The management of postacne scarring.
Topics: Acne Vulgaris; Cicatrix; Face; Humans; Keratolytic Agents; Scalp; Severity of Illness Index | 2007 |
Cicatricial alopecia secondary to radiation therapy: case report and review of the literature.
Topics: Adult; Alopecia; Astrocytoma; Brain Neoplasms; Cicatrix; Female; Hair; Humans; Radiotherapy; Scalp | 2008 |
Cicatricial alopecia secondary to radiation therapy: case report and review of the literature.
Topics: Adult; Alopecia; Astrocytoma; Brain Neoplasms; Cicatrix; Female; Hair; Humans; Radiotherapy; Scalp | 2008 |
Cicatricial alopecia secondary to radiation therapy: case report and review of the literature.
Topics: Adult; Alopecia; Astrocytoma; Brain Neoplasms; Cicatrix; Female; Hair; Humans; Radiotherapy; Scalp | 2008 |
Cicatricial alopecia secondary to radiation therapy: case report and review of the literature.
Topics: Adult; Alopecia; Astrocytoma; Brain Neoplasms; Cicatrix; Female; Hair; Humans; Radiotherapy; Scalp | 2008 |
[Cicatricial alopecias: diagnosis and therapy].
Topics: Alopecia; Biopsy; Cicatrix; Diagnosis, Differential; Hair Follicle; Humans; Prognosis; Scalp | 1997 |
Sarcoma developing in a burn scar: case report and review of the literature.
Topics: Adult; Burns; Cell Transformation, Neoplastic; Cicatrix; Humans; Leiomyosarcoma; Male; Scalp; Skin N | 1998 |
Scarring alopecia and the dermatopathologist.
Topics: Alopecia; Biopsy; Cicatrix; Dermatology; Diagnosis, Differential; Humans; Scalp | 2001 |
Hair transplantation: management of donor area.
Topics: Cicatrix; Hair Follicle; Humans; Scalp; Suture Techniques; Wound Healing | 2002 |
14 trials available for salicylic acid and Cicatrization
Article | Year |
---|---|
Combination treatment with 30% salicylic acid and fractional CO
Topics: Acne Vulgaris; Carbon Dioxide; Cicatrix; Humans; Lasers, Gas; Pain; Prospective Studies; Salicylic A | 2022 |
High-voltage electric stimulation of the donor site of skin grafts accelerates the healing process. A randomized blinded clinical trial.
Topics: Adult; Burns; Cicatrix; Double-Blind Method; Electric Stimulation Therapy; Female; Humans; Male; Mid | 2018 |
Treatment of Postsurgical Scalp Scar Deformity Using Follicular Unit Hair Transplantation.
Topics: Adolescent; Adult; Alopecia; Cicatrix; Female; Hair Follicle; Humans; Male; Scalp | 2019 |
[Clinical study of repairing donor site of thickness from cicatricial skin with auto-scalp grafting].
Topics: Adult; Burns; Cicatrix; Female; Humans; Male; Middle Aged; Scalp; Skin Transplantation; Transplantat | 2013 |
Invisible scar endoscopic dorsal approach thyroidectomy: a clinical feasibility study.
Topics: Adult; Cicatrix; Endoscopy; Feasibility Studies; Female; Humans; Male; Middle Aged; Prospective Stud | 2010 |
Comparison of suture types in the closure of scalp wounds.
Topics: Adult; Aged; Biocompatible Materials; Cicatrix; Female; Humans; Lacerations; Male; Middle Aged; Scal | 2011 |
Treatment of actinic keratoses and photodamage with non-contact fractional 1540-nm laser quasi-ablation: an ex vivo and clinical evaluation.
Topics: Aged; Cicatrix; Edema; Erythema; Face; Female; Humans; Keratosis, Actinic; Laser Therapy; Lasers, So | 2013 |
The influence of peri-incisional triamcinolone acetonide injection on wound edge apposition.
Topics: Adult; Cicatrix; Female; Glucocorticoids; Hair; Humans; Injections, Intradermal; Male; Middle Aged; | 2014 |
Consecutive wide and long single hair-bearing transposition flaps in combination with hair transplantation for the management of slot formation after alopecia reducing surgery.
Topics: Alopecia; Cicatrix; Esthetics; Hair; Hair Diseases; Humans; Postoperative Complications; Scalp; Surg | 1996 |
Reconstruction of burn deformity using artificial dermis combined with thin split-skin grafting.
Topics: Adolescent; Adult; Burns; Child; Child, Preschool; Cicatrix; Contracture; Female; Graft Survival; Hu | 1997 |
Outcomes of irradiated polyglactin 910 Vicryl Rapide fast-absorbing suture in oral and scalp wounds.
Topics: Adult; Biocompatible Materials; Cicatrix; Humans; Lactic Acid; Mouth; Oral Surgical Procedures; Poly | 1999 |
[Local administration of drug during tissue expansion].
Topics: Adolescent; Adult; Anesthetics, Local; Child; Cicatrix; Female; Glucocorticoids; Humans; Male; Middl | 1997 |
A randomized controlled trial comparing the hair apposition technique with tissue glue to standard suturing in scalp lacerations (HAT study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Cicatrix; Female; Follow-Up Stu | 2002 |
Absorbable versus nonabsorbable sutures to prevent postoperative stretching of wound area.
Topics: Absorption; Adult; Benzenesulfonates; Cicatrix; Humans; Polypropylenes; Random Allocation; Scalp; Su | 1986 |
299 other studies available for salicylic acid and Cicatrization
Article | Year |
---|---|
Evaluation of 30% supramolecular salicylic acid followed by 1565-nm non-ablative fractional laser on facial acne and subsequent enlarged pores.
Topics: Acne Vulgaris; Cicatrix; Erythema; Humans; Lasers; Prospective Studies; Salicylic Acid; Treatment Ou | 2023 |
Glycolic acid peels versus salicylic-mandelic acid peels in active acne vulgaris and post-acne scarring and hyperpigmentation: a comparative study.
Topics: Acne Vulgaris; Adolescent; Adult; Chemexfoliation; Cicatrix; Drug Combinations; Female; Glycolates; | 2009 |
[A NEW AGENT CAPABLE OF ACCELERATING CICATRIZATION: DV-511].
Topics: Amputation Stumps; Benzoates; Burns; Cicatrix; Humans; Leg Ulcer; Malates; Postoperative Care; Salic | 1964 |
Salicylic acid may be useful in limiting scar formation.
Topics: Administration, Topical; Anti-Inflammatory Agents; Cicatrix; Combined Modality Therapy; Humans; Hydr | 2004 |
Evaluating the association of central centrifugal cicatricial alopecia (CCCA) and fibroproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Black or African American; Body Mass Index; Cicatrix; Fema | 2021 |
A new aesthetic pretrichial approach for upper third-facial fractures and pathologies: The "Crown incision".
Topics: Cicatrix; Esthetics; Humans; Retrospective Studies; Scalp; Skull Fractures; Surgical Wound | 2022 |
Gene expression profiling suggests severe, extensive central centrifugal cicatricial alopecia may be both clinically and biologically distinct from limited disease subtypes.
Topics: Alopecia; Cicatrix; Dermatitis; Female; Gene Expression Profiling; Hair; Humans; Microarray Analysis | 2022 |
Epicrania fugax originating from a surgical scar of the scalp.
Topics: Cicatrix; Headache; Humans; Scalp | 2022 |
Percutaneous collagen induction (microneedling) for scarring alopecia in discoid lupus erythematosus of the scalp.
Topics: Alopecia; Cicatrix; Humans; Lupus Erythematosus, Discoid; Scalp | 2022 |
Expanded scalp flap combined with laser hair removal to reconstruct facial defects around the hairline.
Topics: Cicatrix; Hair Removal; Humans; Lasers; Nevus; Plastic Surgery Procedures; Retrospective Studies; Sc | 2022 |
The Africa Temporal Scalp Flap: A Novel Flap for Facial Reconstruction.
Topics: Burns; Cicatrix; Humans; Infant; Plastic Surgery Procedures; Retrospective Studies; Scalp | 2023 |
Type 2 diabetes mellitus and central centrifugal cicatricial alopecia severity.
Topics: Alopecia; Cicatrix; Dermatitis; Diabetes Mellitus, Type 2; Humans; Scalp | 2022 |
IL-17 Expression in the Perifollicular Fibrosis in Biopsies From Lichen Planopilaris.
Topics: Alopecia; Biopsy; Cicatrix; Fibrosis; Humans; Interleukin-17; Lichen Planus; Retrospective Studies; | 2022 |
A case of verrucous carcinoma arising from a burn scar on the scalp of an HIV-positive patient.
Topics: Burns; Carcinoma, Verrucous; Cicatrix; HIV Infections; Humans; Scalp; Skin Neoplasms | 2023 |
A case of verrucous carcinoma arising from a burn scar on the scalp of an HIV-positive patient.
Topics: Burns; Carcinoma, Verrucous; Cicatrix; HIV Infections; Humans; Scalp; Skin Neoplasms | 2023 |
A case of verrucous carcinoma arising from a burn scar on the scalp of an HIV-positive patient.
Topics: Burns; Carcinoma, Verrucous; Cicatrix; HIV Infections; Humans; Scalp; Skin Neoplasms | 2023 |
A case of verrucous carcinoma arising from a burn scar on the scalp of an HIV-positive patient.
Topics: Burns; Carcinoma, Verrucous; Cicatrix; HIV Infections; Humans; Scalp; Skin Neoplasms | 2023 |
A case of verrucous carcinoma arising from a burn scar on the scalp of an HIV-positive patient.
Topics: Burns; Carcinoma, Verrucous; Cicatrix; HIV Infections; Humans; Scalp; Skin Neoplasms | 2023 |
A case of verrucous carcinoma arising from a burn scar on the scalp of an HIV-positive patient.
Topics: Burns; Carcinoma, Verrucous; Cicatrix; HIV Infections; Humans; Scalp; Skin Neoplasms | 2023 |
A case of verrucous carcinoma arising from a burn scar on the scalp of an HIV-positive patient.
Topics: Burns; Carcinoma, Verrucous; Cicatrix; HIV Infections; Humans; Scalp; Skin Neoplasms | 2023 |
A case of verrucous carcinoma arising from a burn scar on the scalp of an HIV-positive patient.
Topics: Burns; Carcinoma, Verrucous; Cicatrix; HIV Infections; Humans; Scalp; Skin Neoplasms | 2023 |
A case of verrucous carcinoma arising from a burn scar on the scalp of an HIV-positive patient.
Topics: Burns; Carcinoma, Verrucous; Cicatrix; HIV Infections; Humans; Scalp; Skin Neoplasms | 2023 |
Scalp biopsy influences diagnostic accuracy and treatment in Black women with alopecia: A retrospective study.
Topics: Alopecia; Biopsy; Cicatrix; Female; Hair; Humans; Retrospective Studies; Scalp | 2023 |
A Scalp Scar-Reducing Procedure for the Hair Transplant Donor Area Using a Columnar Trichophytic Suture: A Case Report.
Topics: Adult; Alopecia; Cicatrix; Hair; Humans; Male; Scalp; Sutures; Tissue Donors; Young Adult | 2023 |
A case of scarring and nonscarring alopecia secondary to vascular occlusion with dermal filler.
Topics: Alopecia; Cicatrix; Dermal Fillers; Humans; Scalp; Vascular Diseases | 2023 |
Sarcoidosis Coexisting With Distinct Forms of Alopecia on the Scalp: A Case Series.
Topics: Alopecia; Alopecia Areata; Cicatrix; Humans; Lichen Planus; Sarcoidosis; Scalp | 2023 |
Reconstruction of High-Tension Scalp Defects by the Twizzler Technique: A Retrospective Case Series.
Topics: Cicatrix; Humans; Retrospective Studies; Scalp; Skin Neoplasms; Surgical Flaps; Tissue Expansion | 2023 |
The histopathologic diagnosis of traction alopecia: An evidence-based model.
Topics: Alopecia; Biopsy; Cicatrix; Hair Follicle; Humans; Scalp; Traction | 2023 |
Application of Autologous Hair Transplantation Technique in Children with Cicatricial Alopecia.
Topics: Alopecia; Child; Cicatrix; Female; Hair; Hair Follicle; Humans; Male; Scalp; Skin Transplantation; T | 2023 |
Central centrifugal cicatricial alopecia in males.
Topics: Adult; Alopecia; Black or African American; Cicatrix; Dermatitis; Diabetes Mellitus, Type 2; Female; | 2023 |
Central centrifugal cicatricial alopecia: Beyond the hot comb.
Topics: Alopecia; Cicatrix; Dermatitis; Humans; Scalp | 2023 |
Hair follicle extraction combined with an expanded scalp flap for facial organ reconstruction.
Topics: Cicatrix; Hair Follicle; Hair Removal; Humans; Plastic Surgery Procedures; Scalp; Surgical Flaps | 2023 |
Two-Stage Procedure to Correct Scalp and Facial Scars-Autologous Fat Grafting Before Hair Grafting.
Topics: Cicatrix; Combined Modality Therapy; Face; Female; Hair; Humans; Male; Scalp; Subcutaneous Fat; Tran | 2020 |
Dilation of Multiple Eccrine Ducts as a Highly Specific Marker for Cicatricial Alopecia.
Topics: Alopecia; Biopsy; Cicatrix; Databases, Factual; Diagnosis, Differential; Dilatation, Pathologic; Ecc | 2019 |
Clinical outcomes and technical tips for eyebrow restoration using single-follicular-unit hair transplantation: A case series review.
Topics: Cicatrix; Eyebrows; Hair Follicle; Humans; Scalp; Skin Transplantation | 2020 |
Aplasia cutis congenita of the scalp: Histopathologic features and clinicopathologic correlation in a case series.
Topics: Adolescent; Adult; Child; Child, Preschool; Cicatrix; Ectodermal Dysplasia; Elastic Tissue; Female; | 2020 |
Use of Giemsa staining in the evaluation of central centrifugal cicatricial alopecia.
Topics: Alopecia; Azure Stains; Cicatrix; Hair Follicle; Humans; Scalp; Staining and Labeling | 2020 |
A case of delayed-onset scarring alopecia in a 75-year-old woman.
Topics: Aged; Alopecia; Anastrozole; Aromatase Inhibitors; Biopsy; Bone Density Conservation Agents; Breast | 2020 |
Blistering and scarring confined to the head.
Topics: Aged, 80 and over; Blister; Cicatrix; Epidermolysis Bullosa Acquisita; Face; Female; Head; Humans; S | 2020 |
Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab.
Topics: Alopecia; Antibodies, Monoclonal, Humanized; Cicatrix; Fibrosis; Humans; Lichen Planus; Scalp | 2020 |
Should the beard be considered as a separate facial unit?
Topics: Burns; Cicatrix; Contracture; Esthetics; Facial Injuries; Humans; Islam; Male; Physical Appearance, | 2020 |
Central Centrifugal Cicatricial Alopecia.
Topics: Administration, Oral; Adult; Alopecia; Black or African American; Cicatrix; Female; Glucocorticoids; | 2020 |
Combination Hair Restoration Techniques in the Treatment of Severe Cutis Verticis Gyrata.
Topics: Adult; Alopecia; Cicatrix; Esthetics; Hair Follicle; Humans; Male; Postoperative Complications; Scal | 2021 |
Scalp Micropigmentation Procedure: A Useful Procedure for Hair Restoration.
Topics: Alopecia Areata; Cicatrix; Female; Hair; Humans; Male; Scalp; Tattooing | 2021 |
Vertical or horizontal scalp mobility: What to assess.
Topics: Cicatrix; Hair; Humans; Scalp; Skin | 2021 |
Prefabricated Expanded Flap Combined With Expanded Scalp Flap for Total Face Resurfacing.
Topics: Burns; Cicatrix; Facial Injuries; Humans; Plastic Surgery Procedures; Scalp; Skin Transplantation; S | 2021 |
Corrective strategies for poor appearance after tissue expansion for temporal and sideburn cicatricial alopecia.
Topics: Alopecia; Cicatrix; Hair; Hair Follicle; Humans; Scalp; Skin Transplantation; Tissue Expansion | 2021 |
Closure of Challenging Pediatric Scalp Wounds by a Tension-Relief System.
Topics: Child; Cicatrix; Humans; Plastic Surgery Procedures; Scalp; Surgical Flaps; Tissue Expansion Devices | 2021 |
Case Report: Scarring Alopecia After Scalp Avulsion.
Topics: Alopecia; Amputation, Traumatic; Cicatrix; Humans; Risk Factors; Scalp | 2023 |
Hair Transplantation in Burn Scar Alopecia After Combined Non-Ablative Fractional Laser and Microfat Graft Treatment.
Topics: Alopecia; Cicatrix; Hair; Hair Follicle; Humans; Lasers; Scalp; Skin Transplantation | 2021 |
Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG).
Topics: Alopecia; Cicatrix; Clinical Trials as Topic; Consensus; Guidelines as Topic; Humans; Lichen Planus; | 2021 |
Aesthetic forehead reduction in female patients: Surgical details and analysis of outcome.
Topics: Cicatrix; Esthetics; Female; Forehead; Humans; Prospective Studies; Scalp | 2022 |
Progress in Microdermal Grafting for Color Regeneration of White Scars.
Topics: Cicatrix; Humans; Scalp; Skin; Skin Pigmentation; Skin Transplantation | 2021 |
A Retrospective Review of Treatment Results for Patients With Central Centrifugal Cicatrical Alopecia.
Topics: Administration, Topical; Adult; Alopecia; Biopsy; Black or African American; Black People; Cicatrix; | 2017 |
A case of multifocal scarring alopecia.
Topics: Alopecia; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cicatrix; Fatal Outcome; Fema | 2017 |
Elastic Fibers in Scars and Alopecia.
Topics: Alopecia; Biopsy, Needle; Cicatrix; Elastic Tissue; Humans; Immunohistochemistry; Scalp; Sensitivity | 2017 |
Frontal fibrosing alopecia among men: A clinicopathologic study of 7 cases.
Topics: Adult; Aged; Alopecia; Anti-Inflammatory Agents; Cheek; Cicatrix; Clobetasol; Dermatologic Agents; E | 2017 |
Reconstruction of Large Postburn Facial-Scalp Scars by Expanded Pedicled Deltopectoral Flap and Random Scalp Flap: Technique Improvements to Enlarge the Reconstructive Territory.
Topics: Burns; Cicatrix; Cohort Studies; Face; Humans; Plastic Surgery Procedures; Scalp; Surgical Flaps | 2017 |
Elastic Staining in Differentiating Between Follicular Streamers and Follicular Scars in Horizontal Scalp Biopsy Sections.
Topics: Alopecia; Biopsy; Cicatrix; Elastic Tissue; Hair Follicle; Humans; Scalp; Staining and Labeling | 2018 |
Optical coherence tomography for the investigation of frontal fibrosing alopecia.
Topics: Adult; Aged; Alopecia; Arm; Cicatrix; Epidermis; Eyebrows; Female; Fibrosis; Forehead; Humans; Middl | 2018 |
Resident Rounds Part III: Case Report: Metastatic Cutaneous Squamous Cell Carcinoma in an African American Female.
Topics: Black or African American; Carcinoma, Squamous Cell; Cicatrix; Combined Modality Therapy; Diagnosis, | 2017 |
Percutaneous Mesh Expansion: A Regenerative Wound Closure Alternative.
Topics: Aged; Aged, 80 and over; Cicatrix; Head and Neck Neoplasms; Humans; Middle Aged; Minimally Invasive | 2018 |
Cutaneous Metastases of the Glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cicatrix; Crani | 2018 |
Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia and fibrosing alopecia in a pattern distribution?
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Cicatrix; Dermoscopy; Female; Fibrosis; Humans; Menopause; | 2018 |
Primary scarring alopecia: A retrospective study of 89 patients in Taiwan.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alopecia; Cicatrix; Female; Hair Follicle; | 2018 |
Cicatricial Alopecia Research Foundation meeting, May 2016: Progress towards the diagnosis, treatment and cure of primary cicatricial alopecias.
Topics: Alopecia; Animals; Cicatrix; Disease Models, Animal; Dogs; Fibrosis; Humans; Lichen Planus; Mice; Sc | 2018 |
Scalp as a donor site in children: Is it really the best option?
Topics: Alopecia; Black People; Burns; Child; Child, Preschool; Cicatrix; Cicatrix, Hypertrophic; Cohort Stu | 2018 |
Bibbidi bobbidi bald: Two "hairowing" tales of Princess Package hairstyles.
Topics: Alopecia; Child, Preschool; Cicatrix; Female; Glucaric Acid; Hair; Humans; Minoxidil; Scalp; United | 2018 |
A Predictive Model for Primary Closure Lengths in Mohs Surgery Based on Skin Cancer Type, Dimensions, and Location.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cicatrix; Extremiti | 2019 |
Atrophic and Annular Scarring Alopecia of the Scalp as a Finding in Underlying Systemic Sarcoidosis.
Topics: Aged; Alopecia; Atrophy; Cicatrix; Humans; Male; Sarcoidosis; Scalp | 2017 |
[Frontal and scalp expanded skin flap combined with laser hair removal for children congenital facial giant nevi].
Topics: Adolescent; Child; Cicatrix; Facial Neoplasms; Female; Forehead; Hair Removal; Humans; Male; Neoplas | 2017 |
Measurements of tension on wound edges after strip harvest surgery.
Topics: Adult; Alopecia; Cicatrix; Hair Follicle; Humans; Male; Scalp; Skin; Skin Transplantation; Suture Te | 2019 |
Feature characterization of scarring and non-scarring types of alopecia by multiphoton microscopy.
Topics: Alopecia; Cicatrix; Hair Follicle; Humans; Male; Microscopy, Confocal; Pilot Projects; Prospective S | 2019 |
Scalp Sarcoidosis Presenting as Cicatricial Alopecia.
Topics: Alopecia; Cicatrix; Female; Humans; Middle Aged; Sarcoidosis; Scalp | 2018 |
A review of 31 cases of Marjolin's ulcer on scalp: Is it necessary to preventively remove the scar?
Topics: Adult; Carcinoma, Squamous Cell; China; Cicatrix; Female; Humans; Male; Middle Aged; Retrospective S | 2019 |
Staged reconstructive treatment for extensive irregular cicatricial alopecia after burn.
Topics: Adolescent; Adult; Alopecia; Burns; Child; Cicatrix; Dermatologic Surgical Procedures; Esthetics; Fe | 2018 |
Distinct Patterns of Hair Graft Survival After Transplantation Into 2 Nonhealing Ulcers: Is Location Everything?
Topics: Adolescent; Aged, 80 and over; Arm; Burns; Chronic Disease; Cicatrix; Collagen; Dermis; Graft Surviv | 2019 |
Trichophytic closure for cicatricial alopecia on the scalp.
Topics: Adolescent; Adult; Alopecia; Cicatrix; Craniotomy; Humans; Scalp; Surgical Wound; Wound Closure Tech | 2019 |
Variant
Topics: Adolescent; Adult; Age of Onset; Alopecia; Black or African American; Chi-Square Distribution; Cicat | 2019 |
Frontal fibrosing alopecia: A new autoimmune entity?
Topics: Adult; Aged; Alopecia; Animals; Autoimmune Diseases; Cicatrix; Female; Fibrosis; Humans; Lichen Plan | 2019 |
Use of trichoscopy for the diagnosis of alopecia areata coexisting with primary scarring alopecia in a female hair loss patient.
Topics: Adult; Alopecia Areata; Cicatrix; Dermoscopy; Diagnosis, Differential; Female; Hair; Humans; Scalp | 2019 |
A preliminary study on ultrasound techniques applied to cicatricial alopecia.
Topics: Adult; Alopecia; Cicatrix; Feasibility Studies; Humans; Middle Aged; Scalp; Skin; Ultrasonography; Y | 2019 |
Choosing the right rectangular expander and maximising the benefits from expanded tissue.
Topics: Adolescent; Adult; Burns; Child; Cicatrix; Female; Humans; Male; Nevus; Plastic Surgery Procedures; | 2019 |
Graham-Little-Piccardi-Lassueur syndrome.
Topics: Alopecia; Axilla; Cicatrix; Female; Groin; Hair Diseases; Humans; Middle Aged; Scalp; Syndrome | 2019 |
Clinical Pearl: advantages of the scalp as a split-thickness skin graft donor site.
Topics: Cicatrix; Humans; Male; Middle Aged; Scalp; Skin Transplantation; Transplant Donor Site; Wound Heali | 2019 |
Blink sign in dermatoscopy of cicatricial alopecia.
Topics: Alopecia; Cicatrix; Dermoscopy; Diagnosis, Differential; Fibrosis; Humans; Scalp; Skin | 2019 |
Dermoscopic features of lichen planopilaris in Northern Iran: a prospective observational study.
Topics: Adult; Alopecia; Biopsy; Cicatrix; Dermoscopy; Feasibility Studies; Female; Hair; Hair Diseases; Hum | 2019 |
Versatility of the pinwheel flap to reconstruct circular defects in the temporal and scalp region.
Topics: Adolescent; Adult; Aged; Child; Cicatrix; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged | 2013 |
Follicular density and ratios in scarring and nonscarring alopecia.
Topics: Adult; Alopecia; Biopsy; Cicatrix; Cytodiagnosis; Female; Hair Follicle; Humans; Male; Scalp | 2013 |
Prospective histologic examinations in patients who practice traumatic hairstyling.
Topics: Adult; Alopecia; Beauty Culture; Biopsy; Black or African American; Cicatrix; Female; Fibrosis; Hair | 2013 |
Scoping scalp disorders: practical use of a novel dermatoscope to diagnose hair and scalp conditions.
Topics: Cicatrix; Dermoscopy; Female; Hair; Hair Diseases; Hair Follicle; Humans; Male; Prospective Studies; | 2013 |
[Traction alopecias].
Topics: Alopecia; Beauty Culture; Cicatrix; Diagnosis, Differential; Folliculitis; Humans; Scalp; Stress, Me | 2013 |
Scalp eschar and neck lymphadenopathy caused by Rickettsia massiliae.
Topics: Adolescent; Alopecia; Animals; Bacterial Typing Techniques; Base Sequence; Cicatrix; Dermacentor; DN | 2013 |
Facelift- and circum-occipital incision placement for fat extirpation of the neck in Madelung's disease - a two-case report.
Topics: Cicatrix; Dermatologic Surgical Procedures; Dissection; Endoscopy; Face; Follow-Up Studies; Humans; | 2014 |
Hair follicle transplantation on scar tissue.
Topics: Adolescent; Adult; Burns; Child; Cicatrix; Esthetics; Eyebrows; Eyelids; Female; Follow-Up Studies; | 2013 |
Subcutaneoscopic excision of external angular dermoid cyst in children without conspicuous scarring.
Topics: Child, Preschool; Cicatrix; Dermoid Cyst; Endoscopy; Facial Neoplasms; Feasibility Studies; Humans; | 2013 |
Transversely sectioned biopsies in the diagnosis of end-stage traction alopecia.
Topics: Adult; Alopecia; Beauty Culture; Black or African American; Cicatrix; Female; Hair; Hair Preparation | 2013 |
Comparison of scalp and abdomen as split-thickness skin graft donor sites for aural stenosis repair.
Topics: Abdominal Wall; Adolescent; Adult; Cicatrix; Constriction, Pathologic; Ear, External; Female; Humans | 2014 |
Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cicatrix; Epidermolysis Bullosa; Female; Humans; I | 2014 |
Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cicatrix; Epidermolysis Bullosa; Female; Humans; I | 2014 |
Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cicatrix; Epidermolysis Bullosa; Female; Humans; I | 2014 |
Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cicatrix; Epidermolysis Bullosa; Female; Humans; I | 2014 |
Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cicatrix; Epidermolysis Bullosa; Female; Humans; I | 2014 |
Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cicatrix; Epidermolysis Bullosa; Female; Humans; I | 2014 |
Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cicatrix; Epidermolysis Bullosa; Female; Humans; I | 2014 |
Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cicatrix; Epidermolysis Bullosa; Female; Humans; I | 2014 |
Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI).
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cicatrix; Epidermolysis Bullosa; Female; Humans; I | 2014 |
Micropigmentation: camouflaging scalp alopecia and scars in Korean patients.
Topics: Adult; Alopecia; Asian People; Cicatrix; Female; Humans; Male; Middle Aged; Retrospective Studies; S | 2014 |
Editor's invited commentary: Micropigmentation: camouflaging scalp alopecia and scars in Korean patients.
Topics: Alopecia; Cicatrix; Female; Humans; Male; Scalp; Tattooing | 2014 |
Isolated linear lichen planopilaris: extremely rare when limited to the scalp.
Topics: Adult; Cicatrix; Follow-Up Studies; Forehead; Humans; Lichen Planus; Male; Scalp | 2013 |
Fetal laceration during caesarean section and its medico-legal sequelae.
Topics: Cesarean Section; Cicatrix; Compensation and Redress; Facial Injuries; Female; Fetus; Humans; Italy; | 2015 |
Gland-preserving robotic surgery for benign submandibular gland tumours: a comparison between robotic and open techniques.
Topics: Adenoma, Pleomorphic; Adult; Blood Loss, Surgical; Case-Control Studies; Cicatrix; Cohort Studies; D | 2014 |
Pathologic diagnosis of central centrifugal cicatricial alopecia on horizontal sections.
Topics: Adolescent; Adult; Alopecia; Biopsy; Black or African American; Cicatrix; Female; Hair Follicle; Hum | 2014 |
[Alopecia reconstruction by expansion after a scalp burn injury caused by Taser(®): a case report].
Topics: Alopecia; Burns, Electric; Cicatrix; Conducted Energy Weapon Injuries; Equipment Design; Esthetics; | 2014 |
Measuring occipital scalp laxity before donor strip harvesting in hair transplantation.
Topics: Adult; Cicatrix; Hair; Hair Follicle; Humans; Male; Retrospective Studies; Scalp; Treatment Outcome | 2014 |
Zigzag skin incision effectively camouflages the scar and alopecia for moyamoya disease: technical note.
Topics: Adolescent; Adult; Alopecia; Cerebral Revascularization; Child; Cicatrix; Craniotomy; Female; Humans | 2015 |
Sarcoidosis presenting as non-scarring non-scalp alopecia.
Topics: Adult; Alopecia; Biopsy, Needle; Cicatrix; Diagnosis, Differential; Humans; Immunohistochemistry; Lo | 2016 |
Double-Opposing Unilobar Rotation Flaps in the Reconstruction of Moderate-to-Large Defects of the Scalp.
Topics: Aged; Alopecia; Blood Loss, Surgical; Carcinoma, Squamous Cell; Child; Cicatrix; Female; Graft Survi | 2015 |
Treatment of Thin Linear Scars on the Scalp.
Topics: Cicatrix; Esthetics; Humans; Scalp; Suture Techniques | 2015 |
Commentary for Treatment of Thin Linear Scars on the Scalp.
Topics: Cicatrix; Humans; Scalp; Suture Techniques | 2015 |
[Modified purse string suture to reduce the size of surgical defect].
Topics: Cicatrix; Dermatologic Surgical Procedures; Humans; Scalp; Skin; Skin Neoplasms; Suture Techniques; | 2016 |
[Scalp surface skin grafts in reconstruction of external auditory meatus in congenital aural atresia].
Topics: Adolescent; Adult; Child; Cicatrix; Congenital Abnormalities; Constriction, Pathologic; Ear; Ear Can | 2016 |
[Scalp expanded flap combined with IPL hair removal for large area scar on forehead].
Topics: Cicatrix; Forehead; Graft Survival; Hair Removal; Humans; Scalp; Surgical Flaps; Tissue Expansion; T | 2015 |
Forehead Mass Removal by Endoscopic Approach.
Topics: Cicatrix; Endoscopy; Esthetics; Forehead; Humans; Osteoma; Postoperative Care; Postoperative Complic | 2016 |
Free perforating branch flap for primary repairing the huge soft-tissue defects on the scalp and face.
Topics: Adult; Aged; Cicatrix; Face; Female; Humans; Male; Middle Aged; Plastic Surgery Procedures; Scalp; S | 2016 |
Reflectance confocal microscopy for scarring and non-scarring alopecia real-time assessment.
Topics: Alopecia Areata; Biopsy; Cicatrix; Dermoscopy; Diagnosis, Differential; Female; Humans; Lichen Planu | 2016 |
Commentary on Association Between Scalp Laxity, Elasticity, and Glidability and Donor Strip Scar Width in Hair Transplantation and a New Elasticity Measuring Method.
Topics: Alopecia; Cicatrix; Elasticity; Hair; Humans; Scalp; Skin | 2017 |
A histologic review of 27 patients with lichen planopilaris.
Topics: Adult; Aged; Alopecia; Biopsy; Cicatrix; Female; Humans; Lichen Planus; Male; Middle Aged; Retrospec | 2008 |
Repair of faciocervical scars by expanded deltopectoral flap.
Topics: Adolescent; Adult; Burns; Child; Cicatrix; Drainage; Facial Injuries; Female; Humans; Male; Mammary | 2008 |
The use of micrografts and minigrafts together with advancement of temporalis fascia and its periosteum on the treatment of burn alopecia.
Topics: Adult; Alopecia; Burns; Cicatrix; Fascia; Graft Survival; Hair; Humans; Male; Microsurgery; Muscle, | 2008 |
Marjolin ulcer of the scalp: intruder of a burn scar.
Topics: Adult; Aged; Aged, 80 and over; Burns; Carcinoma, Squamous Cell; Cicatrix; Female; Humans; Male; Mid | 2008 |
A great Marjolin's ulcer of the scalp invading outer calvarial bone and its different treatment with support of Medpor.
Topics: Adult; Biocompatible Materials; Burns; Carcinoma, Squamous Cell; Cicatrix; Craniotomy; Female; Human | 2008 |
Aesthetic pubic reconstruction after electrical burn using a portion of hair-bearing expanded free-forehead flap.
Topics: Burns, Electric; Cicatrix; Forehead; Genitalia, Male; Humans; Male; Plastic Surgery Procedures; Scal | 2009 |
Frontal fibrosing alopecia: clinical presentations and prognosis.
Topics: Adult; Aged; Alopecia; Cicatrix; Disease Progression; Eyebrows; Female; Fibrosis; Forehead; Hair Fol | 2009 |
Cicatricial marginal alopecia: is it all traction?
Topics: Adolescent; Adult; Alopecia; Biopsy; Cicatrix; Diagnosis, Differential; Female; Hair Follicle; Human | 2009 |
Scar of scalp, site of growth removed by chemical means.
Topics: Cicatrix; Humans; Neoplasms; Scalp | 1948 |
Hair restoration complications: an approach to the unnatural-appearing hair transplant.
Topics: Alopecia; Cicatrix; Esthetics; Female; Hair Follicle; Humans; Male; Scalp; Skin Transplantation; Tis | 2008 |
Refractory dissecting cellulitis of the scalp treated with adalimumab.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cel | 2008 |
Reconstruction of facial defects using prefabricated expanded flaps carried by temporoparietal fascia flaps.
Topics: Adolescent; Burns; Child; Child, Preschool; Cicatrix; Face; Facial Neoplasms; Female; Hemangioma; Hu | 2009 |
Tinea capitis mimicking cicatricial alopecia: what host and dermatophyte factors lead to this unusual clinical presentation?
Topics: Abscess; Adolescent; Alopecia; Child; Cicatrix; Dermatitis, Atopic; Diagnosis, Differential; Female; | 2009 |
Purse-string closure of hemangiomas: early results of a follow-up study.
Topics: Cheek; Child; Child, Preschool; Cicatrix; Eyebrows; Female; Follow-Up Studies; Forehead; Head and Ne | 2009 |
The role of dermoscopy in the diagnosis of cicatricial marginal alopecia.
Topics: Adult; Aged; Alopecia; Cicatrix; Dermoscopy; Female; Hair Follicle; Humans; Middle Aged; Scalp | 2009 |
Basal cell carcinoma presenting late in a shotgun scar.
Topics: Aged; Carcinoma, Basal Cell; Cicatrix; Diagnosis, Differential; Humans; Male; Scalp; Skin Neoplasms; | 2009 |
Scarring alopecia: clinical and pathologic study of 54 African-American women.
Topics: Adult; Aged; Alopecia; Biopsy; Black or African American; Cicatrix; Female; Hair Follicle; Hair Prep | 2009 |
Penetrating Marjolin's ulcer of scalp involving bone, dura mater and brain caused by blunt trauma to the burned area.
Topics: Burns; Carcinoma, Squamous Cell; Cerebral Cortex; Cicatrix; Debridement; Dura Mater; Fatal Outcome; | 2009 |
Anatomical variations of the occipital nerves: implications for the treatment of chronic headaches.
Topics: Cicatrix; Cranial Nerves; Decompression, Surgical; Headache Disorders; Humans; Neuralgia; Occipital | 2009 |
Reminders about wound closure.
Topics: Cicatrix; Humans; Lacerations; Scalp; Surgical Stapling; Wound Healing | 2009 |
Versatility of free SCIA/SIEA flaps in head and neck defects.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bone Transplantation; Burns; Carcinoma, Basal Cell; Carcino | 2010 |
Scarring alopecia followed by a progressive eruption.
Topics: Alopecia; Biopsy; Cicatrix; Disease Progression; Humans; Male; Middle Aged; Scalp | 2010 |
The use of the flexible scalpel for minimally invasive and minimally scarring surgery: a case series of four patients with large scalp tumors.
Topics: Aged; Cicatrix; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Minimally Invasive Surgi | 2010 |
Expanded flap and hair follicle transplantation for reconstruction of postburn scalp alopecia.
Topics: Abscess; Adolescent; Adult; Alopecia; Burns; Burns, Electric; Child; Child, Preschool; Cicatrix; Dev | 2010 |
Primary cutaneous follicle centre cell lymphoma of the scalp presenting with scarring alopecia.
Topics: Alopecia; Biopsy; Cicatrix; Female; Head and Neck Neoplasms; Humans; Lymphoma, Follicular; Middle Ag | 2011 |
[A pronounced scar in an 80-year-old patient. (Not) a saber wound. Scleroderma en coup de sabre].
Topics: Aged, 80 and over; Cicatrix; Diagnosis, Differential; Forehead; Humans; Male; Scalp; Scalp Dermatose | 2011 |
Necrosis of the donor site after hair restoration with follicular unit extraction (FUE): a case report.
Topics: Alopecia; Cicatrix; Hair Follicle; Humans; Male; Necrosis; Postoperative Complications; Scalp; Trans | 2012 |
[Surgery of burn sequelae on the scalp].
Topics: Burns; Cicatrix; Humans; Learning Curve; Plastic Surgery Procedures; Practice Guidelines as Topic; S | 2011 |
The scalp or how to reduce the scarring associated with the harvesting of a split-thickness skin graft in head and neck surgery.
Topics: Cicatrix; Head and Neck Neoplasms; Humans; Plastic Surgery Procedures; Scalp; Skin Transplantation; | 2012 |
Long-term results in scalp tissue expansion in children.
Topics: Child; Child, Preschool; Cicatrix; Female; Follow-Up Studies; Humans; Infant; Male; Prostheses and I | 2012 |
Frontal fibrosing alopecia: a retrospective review of 19 patients seen at Duke University.
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Alopecia; Anti-Bacterial Agents; Azasteroids; Cicatrix; D | 2013 |
Surgical anatomy of the scalp.
Topics: Biomechanical Phenomena; Cicatrix; Elasticity; Esthetics; Humans; Scalp | 2002 |
Surgical treatment of aplasia cutis congenita of the scalp associated with bilateral coronal synostosis.
Topics: Alopecia; Bone Transplantation; Cicatrix; Craniosynostoses; Ectodermal Dysplasia; Follow-Up Studies; | 2002 |
New treatment of a visible linear scar in the scalp: multiple hair-bearing flap technique.
Topics: Adolescent; Adult; Alopecia; Child; Cicatrix; Female; Hair; Humans; Male; Plastic Surgery Procedures | 2002 |
Assessment of facial tissue expansion with three-dimensional digitizer scanning.
Topics: Adolescent; Burns; Cicatrix; Computer Graphics; Computer-Aided Design; Contracture; Face; Facial Inj | 2002 |
Striae distensae-like lesions. A cause of scarring alopecia among children.
Topics: Alopecia Areata; Atrophy; Child; Child, Preschool; Cicatrix; Diagnosis, Differential; Female; Humans | 2002 |
Facial reconstruction with combined facial, neck and occipital skin flap transplantation.
Topics: Adult; Aged; Carcinoma, Basal Cell; Cicatrix; Face; Female; Humans; Male; Middle Aged; Neck; Orbital | 2002 |
Surgical pearl: Scalpel dermabrasion complements shave excision.
Topics: Cicatrix; Dermabrasion; Humans; Scalp; Skin Diseases; Surgical Instruments | 2003 |
Algorithm of hair restoration surgery in children.
Topics: Adolescent; Alopecia; Child; Child, Preschool; Cicatrix; Female; Hair; Humans; Male; Radiation Injur | 2003 |
Replacement of scar with hair-bearing scalp.
Topics: Cicatrix; Hair; Head; Humans; Plastics; Replantation; Scalp; Surgery, Plastic | 1954 |
TREATMENT OF ALOPECIA CICATRICANS USING AN ARTERY FLAP.
Topics: Alopecia; Cicatrix; Humans; Scalp; Temporal Arteries; Vascular Surgical Procedures | 1965 |
Scarring alopecia associated with mastocytosis.
Topics: Alopecia; Cicatrix; Diagnosis, Differential; Female; Humans; Mast Cells; Mastocytosis, Cutaneous; Mi | 2003 |
The expanded transposition flap: shifting paradigms based on experience gained from two decades of pediatric tissue expansion.
Topics: Child; Cicatrix; Contracture; Extremities; Face; Female; Humans; Male; Neck; Nevus, Pigmented; Plast | 2004 |
Clinical and basic research on occipito-cervico-dorsal flaps: including a study of the anatomical territories of dorsal trunk vessels.
Topics: Adolescent; Adult; Angiography; Arteries; Child; Cicatrix; Contracture; Face; Female; Graft Survival | 2004 |
The "silicone suture" for tissue expansion without an expander: a new device for repair of soft-tissue defects after burns.
Topics: Abdomen; Adolescent; Adult; Alopecia; Burns; Cicatrix; Dermatologic Surgical Procedures; Female; Hum | 2004 |
Scalp reconstruction with island hair-bearing flaps.
Topics: Adult; Aged; Cicatrix; Female; Hair Diseases; Humans; Male; Pilomatrixoma; Plastic Surgery Procedure | 2005 |
A case of lupus erythematosus profundus with unusual manifestations.
Topics: Adolescent; Axilla; Cicatrix; Complement C3; Female; Fluorescent Antibody Technique; Forearm; Groin; | 2005 |
[Surgical management of cutaneous pathomimia. A report case].
Topics: Cicatrix; Face; Factitious Disorders; Female; Humans; Middle Aged; Plastic Surgery Procedures; Scalp | 2005 |
[The use of superficial cervical artery island skin flaps in the repair of the maxillofacial and cervical scar].
Topics: Adolescent; Adult; Carotid Arteries; Child; Cicatrix; Female; Follow-Up Studies; Humans; Male; Maxil | 2005 |
[Repair of large cicatricial alopecia with skin soft-tissue expansion].
Topics: Adolescent; Adult; Alopecia; Child; Child, Preschool; Cicatrix; Female; Follow-Up Studies; Humans; M | 2005 |
Cutaneous metastasis from glioblastoma.
Topics: Brain Neoplasms; Cicatrix; Craniotomy; Fatal Outcome; Glioblastoma; Head and Neck Neoplasms; Humans; | 2005 |
[Scalp surgery in children: principles and therapeutic aspects].
Topics: Adolescent; Alopecia; Child; Child, Preschool; Cicatrix; Craniocerebral Trauma; Ectodermal Dysplasia | 2005 |
Female pattern hair loss and its relationship to permanent/cicatricial alopecia: a new perspective.
Topics: Alopecia; Black or African American; Cicatrix; Female; Fibrosis; Hair Follicle; Humans; Scalp | 2005 |
Large, nonhealing scalp ulcer associated with scarring alopecia and sclerodermatous change in a patient with porphyria cutanea tarda.
Topics: Alanine Transaminase; Alopecia; Aspartate Aminotransferases; Blood Sedimentation; Cicatrix; Hepatiti | 2005 |
The scalp is an advantageous donor site for thin-skin grafts: a report on 945 harvested samples.
Topics: Cicatrix; Female; Humans; Male; Middle Aged; Reoperation; Retrospective Studies; Scalp; Skin Transpl | 2006 |
[Diagnostic image (285). A young woman with an incurable head wound].
Topics: Adult; Burns; Cell Transformation, Neoplastic; Cicatrix; Fatal Outcome; Female; Humans; Scalp; Skin | 2006 |
[Tissue expansion in surgical treatment of burn scars of the scalp].
Topics: Adolescent; Alopecia; Burns; Child; Child, Preschool; Cicatrix; Humans; Male; Scalp; Tissue Expansio | 2007 |
[A "silicone suture" technique aided to scalp reduction for the treatment of scarring alopecia].
Topics: Adolescent; Adult; Alopecia; Cicatrix; Female; Humans; Male; Scalp; Silicones; Sutures; Young Adult | 2007 |
Staged hair transplantation in cicatricial alopecia after carbon dioxide laser-assisted scar tissue remodeling.
Topics: Adult; Alopecia; Cicatrix; Female; Hair; Humans; Laser Therapy; Male; Scalp; Transplantation, Autolo | 2007 |
Purse-string closure of scalp defects following tissue expansion: an effective aesthetic alternative.
Topics: Child; Cicatrix; Esthetics; Hamartoma; Humans; Male; Reoperation; Scalp; Scalp Dermatoses; Suture Te | 2008 |
Lassueur-Graham-Little-Piccardi syndrome.
Topics: Alopecia; Axilla; Biopsy; Cicatrix; Diagnosis, Differential; Follow-Up Studies; Humans; Male; Middle | 2007 |
[Skin expansion in cicatricial alopecia of the scalp: 18 cases].
Topics: Adolescent; Adult; Aged; Alopecia; Burns; Cicatrix; Female; Humans; Male; Middle Aged; Plastic Surge | 2007 |
Cross-sectional study of hair loss patterns in 122 Korean systemic lupus erythematosus patients: a frequent finding of non-scarring patch alopecia.
Topics: Adolescent; Adult; Aged; Alopecia; Cicatrix; Cross-Sectional Studies; Female; Humans; Korea; Lupus E | 2007 |
Long-term hair repigmentation following a hair transplant for frontal scarring alopecia.
Topics: Alopecia; Cicatrix; Female; Hair Color; Hair Follicle; Humans; Middle Aged; Scalp; Transplantation, | 2007 |
The repair in the scars of the scalp.
Topics: Cicatrix; Craniocerebral Trauma; Humans; Scalp | 1948 |
External tissue expansion in head and neck reconstruction.
Topics: Adolescent; Adult; Burns; Child; Cicatrix; Contracture; Face; Female; Humans; Male; Neck; Scalp; Tis | 2009 |
Aesthetic considerations in scalp reconstruction.
Topics: Alopecia; Cicatrix; Esthetics; Hair; Hair Follicle; Head and Neck Neoplasms; Humans; Microcirculatio | 2008 |
Post-burn head and neck reconstruction using tissue expanders.
Topics: Adolescent; Adult; Burns; Cicatrix; Facial Injuries; Female; Humans; Male; Middle Aged; Neck Injurie | 2008 |
Tick-borne lymphadenopathy/dermacentor-borne necrosis erythema lymphadenopathy: an infectious cause of cicatricial alopecia.
Topics: Alopecia; Animals; Child, Preschool; Cicatrix; Dermacentor; Erythema; Humans; Lymphatic Diseases; Ma | 2008 |
[Follicular psoriasis with cicatricial alopecia. Piccardi-Lassueur-Graham Little syndrome of a psoriatic nature].
Topics: Adult; Alopecia; Cicatrix; Etretinate; Female; Foot; Humans; Pregnancy; Pregnancy Complications; Pso | 1983 |
Complications of scalp reductions.
Topics: Alopecia; Anesthesia; Cicatrix; Esthetics; Foreign Bodies; Hair; Humans; Intraoperative Complication | 1983 |
Penetrating Marjolin's ulcer of scalp involving bone and dura mater treated by wide excision and direct application of a split-skin graft on the brain: a 10-year follow-up.
Topics: Brain; Carcinoma, Squamous Cell; Cicatrix; Dura Mater; Female; Follow-Up Studies; Humans; Middle Age | 1984 |
Soft-tissue expansion: concepts and complications.
Topics: Adult; Aged; Breast; Child; Cicatrix; Connective Tissue; Equipment Failure; Female; Hemorrhage; Huma | 1984 |
Hair transplantation with microsurgical free scalp flap.
Topics: Adult; Alopecia; Burns; Child, Preschool; Cicatrix; Female; Hair; Humans; Male; Microsurgery; Scalp; | 1984 |
The face-lift incision.
Topics: Cicatrix; Esthetics; Face; Female; Humans; Male; Scalp; Surgery, Plastic | 1984 |
[Therapy of cicatricial alopecia caused by burns in the child].
Topics: Alopecia; Burns; Child; Child, Preschool; Cicatrix; Female; Humans; Male; Scalp; Surgical Flaps | 1983 |
[Exeresis in occipital neuralgia].
Topics: Adult; Cervical Vertebrae; Cicatrix; Female; Headache; Humans; Male; Middle Aged; Neuralgia; Neuroma | 1983 |
[Association of melanoma and spinocellular epithelioma on a burn scar of the scalp].
Topics: Burns; Carcinoma, Squamous Cell; Child, Preschool; Cicatrix; Humans; Male; Melanoma; Neoplasms, Mult | 1983 |
Microvascular transplant of two free scalp flaps between identical twins.
Topics: Adult; Cicatrix; Female; Humans; Pregnancy; Scalp; Surgical Flaps; Twins; Twins, Monozygotic | 1982 |
Fiber implantation for pattern baldness. Review of complications in forty-one patients.
Topics: Acrylates; Adult; Alopecia; Cicatrix; Edema; Female; Foreign-Body Reaction; Hair; Humans; Male; Post | 1981 |
Split skin grafts from the scalp.
Topics: Adolescent; Burns; Child; Child, Preschool; Cicatrix; Fear; Hair; Humans; Infant; Methods; Pain; Pos | 1981 |
Complications of fiber implantation for baldness.
Topics: Adult; Alopecia; Cicatrix; Foreign-Body Reaction; Graft Rejection; Hair; Humans; Male; Polymers; Sca | 1981 |
Surgical treatment of cicatricial alopecia of the scalp.
Topics: Adult; Alopecia; Burns; Child; Child, Preschool; Cicatrix; Female; Hair; Humans; Infant; Male; Middl | 1982 |
Angiosarcoma (angioendothelioma) of the scalp. An unusual case of scarring alopecia.
Topics: Aged; Alopecia; Cicatrix; Female; Hemangiosarcoma; Humans; Scalp; Skin Neoplasms | 1980 |
Malignant transformation of a scar in the scalp.
Topics: Carcinoma, Squamous Cell; Cicatrix; Humans; Male; Middle Aged; Radiography; Scalp; Skin Neoplasms; S | 1981 |
Predicting hair growth for hair transplantations.
Topics: Alopecia; Cicatrix; Evaluation Studies as Topic; Hair; Hemorrhage; Humans; Postoperative Complicatio | 1981 |
Scalp reduction for correction of cutis aplasia congenita.
Topics: Adolescent; Cicatrix; Humans; Male; Methods; Scalp | 1981 |
Our experiences with the free latissimus dorsi myocutaneous flap.
Topics: Adolescent; Adult; Aged; Back; Child; Cicatrix; Contracture; Female; Humans; Leg; Male; Methods; Mus | 1980 |
Mini-slit graft hair transplantation using the Ultrapulse carbon dioxide laser handpiece.
Topics: Adult; Alopecia; Cicatrix; Female; Follow-Up Studies; Hair; Humans; Laser Therapy; Male; Postoperati | 1995 |
Scalp reductions.
Topics: Alopecia; Cicatrix; Humans; Laser Therapy; Scalp; Surgery, Plastic | 1995 |
New devices for scalp reduction. Intraoperative and prolonged scalp extension.
Topics: Alopecia; Cicatrix; Dermatology; Equipment Design; Humans; Intraoperative Care; Male; Postoperative | 1995 |
[Scarring psoriatic alopecia].
Topics: Adult; Alopecia; Cicatrix; Diagnosis, Differential; Female; Hair; Humans; Psoriasis; Scalp; Scalp De | 1995 |
[Complications of synthetic hair implantation].
Topics: Adult; Alopecia; Bacterial Infections; Biocompatible Materials; Cicatrix; Expert Testimony; Follicul | 1995 |
Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution.
Topics: Aged; Alopecia; Cicatrix; Female; Fibrosis; Humans; Middle Aged; Postmenopause; Scalp | 1994 |
[Experimental study and clinical use of rapid expansion of skin].
Topics: Adolescent; Adult; Animals; Child; Cicatrix; Dogs; Humans; Male; Scalp; Skin; Tissue Expansion | 1994 |
[Cross transposition of expanded scalp flaps for the treatment of postburn cicatricial alopecia].
Topics: Adolescent; Adult; Alopecia; Burns; Cicatrix; Female; Humans; Male; Scalp; Surgical Flaps; Tissue Ex | 1994 |
Complications of artificial hair implantation.
Topics: Cicatrix; Erythema; Hair; Humans; Male; Middle Aged; Prostheses and Implants; Scalp; Scalp Dermatose | 1994 |
The coronal incision revisited.
Topics: Child; Cicatrix; Female; Humans; Scalp; Skull; Surgery, Plastic | 1994 |
Comparison of skin hooks and Foley catheters for immediate tissue expansion.
Topics: Aged; Aged, 80 and over; Catheterization; Cicatrix; Dermatologic Surgical Procedures; Elasticity; Eq | 1993 |
Spotted cicatricial alopecia in dark skin. A dermoscopic clue to fibrous tracts.
Topics: Adult; Alopecia; Black People; Cicatrix; Female; Hair; Humans; Scalp; Skin Pigmentation | 1993 |
Modified coronal incision: distribution of stress in the scalp and cranium.
Topics: Cicatrix; Elasticity; Esthetics; Hair; Humans; Models, Biological; Osteotomy; Parietal Bone; Scalp; | 1993 |
Total scalp replantation based on one artery and one vein.
Topics: Adult; Anastomosis, Surgical; Arteries; Cicatrix; Eyebrows; Female; Graft Survival; Hair; Humans; Mi | 1993 |
Trichilemmal carcinoma developing in a burn scar: a report of two cases.
Topics: Adult; Aged; Burns; Cicatrix; Cytoplasm; Epidermis; Humans; Keratins; Leg Injuries; Male; Neoplasms, | 1996 |
The necessity for aggressive treatment with Marjolin's ulcers of the scalp.
Topics: Adult; Burns; Carcinoma, Squamous Cell; Cicatrix; Female; Humans; Neoplasm Recurrence, Local; Neopla | 1997 |
Follicular mucinosis associated with scarring alopecia, oligoclonal T-cell receptor V beta expansion, and Staphylococcus aureus: when does follicular mucinosis become mycosis fungoides?
Topics: Adult; Alopecia; Biopsy; Cicatrix; Diagnosis, Differential; Female; Gene Rearrangement, beta-Chain T | 1997 |
Frontal fibrosing alopecia in a postmenopausal woman.
Topics: Alopecia; Cicatrix; Diagnosis, Differential; Female; Humans; Middle Aged; Postmenopause; Scalp | 1997 |
The microdissection cautery needle versus the cold scalpel in bicoronal incisions.
Topics: Alopecia; Cicatrix; Craniosynostoses; Dissection; Electrocoagulation; Electrosurgery; Esthetics; Hem | 1998 |
Prevention and treatment of wide scar and alopecia in the scalp: wedge excision and double relaxation suture.
Topics: Adolescent; Adult; Alopecia; Child; Cicatrix; Female; Humans; Male; Plastic Surgery Procedures; Scal | 1999 |
Free adipofascial flap for scalp reconstruction: case report.
Topics: Adipose Tissue; Aged; Cicatrix; Fascia; Female; Follow-Up Studies; Hemangiosarcoma; Humans; Scalp; S | 1999 |
Coronal incision extending postauricularly.
Topics: Cicatrix; Humans; Scalp | 1999 |
Cicatricial fibromatosis mimics metastatic medulloblastoma.
Topics: Adolescent; Cerebellar Neoplasms; Cicatrix; Diagnosis, Differential; Fibroma; Humans; Male; Medullob | 1999 |
POEMS syndrome: cicatricial alopecia as an unusual cutaneous manifestation associated with an underlying plasmacytoma.
Topics: Adult; Alopecia; Castleman Disease; Cicatrix; Hair Diseases; Humans; Male; Movement Disorders; Paran | 1999 |
[Measurement of skin area of expansion and defect on scalp].
Topics: Adult; Alopecia; Anthropometry; Burns; Cicatrix; Female; Humans; Scalp; Tissue Expansion | 1997 |
[Prevention and treatment of postoperative complications following skin soft tissue expansion].
Topics: Adolescent; Adult; Alopecia; Burns; Child; Child, Preschool; Cicatrix; Face; Female; Humans; Male; M | 1998 |
Hair repair surgery. Corrective measures for improvement of older large-graft procedures and scalp scars.
Topics: Cicatrix; Hair; Humans; Male; Microsurgery; Postoperative Complications; Reoperation; Scalp | 1999 |
Hiding the posterior scar in rhytidectomy: the omega incision.
Topics: Cicatrix; Dissection; Female; Humans; Male; Middle Aged; Rhytidoplasty; Scalp; Surgical Flaps | 1999 |
Malignant fibrous histiocytoma developing in a burn scar.
Topics: Adult; Biopsy; Burns; Cicatrix; Diagnosis, Differential; Female; Histiocytoma, Benign Fibrous; Human | 1999 |
Technical refinements in surgical treatment of benign parotid tumours.
Topics: Adenolymphoma; Adenoma, Pleomorphic; Cicatrix; Ear, External; Face; Humans; Oral Surgical Procedures | 1999 |
[The importance of early surgery in preventing the esthetic sequelae of cervicofacial mucocutaneous hemangiomas in children].
Topics: Child, Preschool; Cicatrix; Esthetics, Dental; Facial Neoplasms; Head and Neck Neoplasms; Hemangioma | 2000 |
Acne keloidalis is a form of primary scarring alopecia.
Topics: Acne Keloid; Adolescent; Adult; Alopecia; Biopsy, Needle; Cicatrix; Hair; Humans; Male; Prospective | 2000 |
Immediate hair transplantation into a newly closed wound to conceal the final scar on the hair-bearing skin.
Topics: Adult; Cicatrix; Combined Modality Therapy; Eyebrows; Female; Hair; Humans; Male; Middle Aged; Scalp | 2000 |
Inadvertant and undesirable sequelae of the stellate purse-string closure.
Topics: Cicatrix; Dermatology; Humans; Plastic Surgery Procedures; Scalp; Sensitivity and Specificity; Sutur | 2000 |
Er:YAG laser-assisted hair transplantation in cicatricial alopecia.
Topics: Alopecia; Cicatrix; Female; Hair; Humans; Laser Therapy; Male; Scalp; Transplantation, Autologous | 2000 |
[Soft tissue reconstruction after scalping injury caused by a dog bite].
Topics: Animals; Bites and Stings; Child; Child, Preschool; Cicatrix; Dogs; Follow-Up Studies; Humans; Male; | 2000 |
[Progressive cicatricial psoriatic alopecia in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Alopecia; Biopsy; Cicatrix; Humans; Male; Scalp; Scalp De | 2000 |
Micropigmentation as an adjuvant in cosmetic surgery of the scalp.
Topics: Cicatrix; Cosmetic Techniques; Female; Ferric Compounds; Humans; Male; Patient Satisfaction; Pigment | 2001 |
Folliculitis decalvans and tufted folliculitis are specific infective diseases that may lead to scarring, but are not a subset of central centrifugal scarring alopecia.
Topics: Alopecia; Cicatrix; Folliculitis; Humans; Scalp; Staphylococcal Infections | 2001 |
[Conversion from a tridimensional surface to a plane for measuring expanded skin area with computer-aided technique].
Topics: Adult; Cicatrix; Female; Humans; Image Processing, Computer-Assisted; Male; Scalp; Skin Transplantat | 1999 |
[Treating cicatricial baldness with scalp expanding and hair autografting].
Topics: Adolescent; Adult; Alopecia; Cicatrix; Female; Hair; Humans; Male; Middle Aged; Scalp; Tissue Expans | 2001 |
The sandwich temporoparietal free fascial flap for tendon gliding.
Topics: Adult; Ankle Injuries; Child; Cicatrix; Fascia; Female; Graft Survival; Hand Injuries; Humans; Male; | 2001 |
[Experience in using complex flaps on microvascular anastomoses in treating with skin cancer on the face and scalp, appearing in scarred areas].
Topics: Anastomosis, Surgical; Cicatrix; Face; Female; Humans; Male; Middle Aged; Scalp; Skin Neoplasms; Sur | 2001 |
Face lifts with hidden scars: the vertical U incision.
Topics: Cicatrix; Female; Humans; Male; Middle Aged; Retrospective Studies; Rhytidoplasty; Scalp | 2002 |
[The clinical application of scalp expansion in the repair of cicatricial baldness in children].
Topics: Adolescent; Alopecia; Burns; Child; Cicatrix; Female; Humans; Male; Scalp; Tissue Expansion | 1999 |
Hair apposition for scalp lacerations.
Topics: Adult; Child; Cicatrix; Hair; Hemorrhage; Humans; Lacerations; Observer Variation; Research Design; | 2002 |
Extensive cicatrical alopecia following scalp vein infusion.
Topics: Adolescent; Alopecia; Bicarbonates; Cicatrix; Drug Eruptions; Fluid Therapy; Humans; Male; Scalp | 1979 |
[The scalp: donor area for thin grafts].
Topics: Adolescent; Adult; Aged; Child; Cicatrix; Female; Humans; Male; Middle Aged; Scalp; Skin; Skin Trans | 1977 |
Soft tissue injuries of face and scalp.
Topics: Adolescent; Child; Child, Preschool; Cicatrix; Dermatologic Surgical Procedures; Facial Injuries; Fe | 1977 |
Microvascular free skin flap transfer.
Topics: Adult; Child; Cicatrix; Face; Female; Humans; Inguinal Canal; Leg; Male; Microsurgery; Middle Aged; | 1978 |
Scalp reduction for alopecia.
Topics: Adolescent; Alopecia; Cicatrix; Hair; Humans; Male; Methods; Scalp; Transplantation, Autologous | 1979 |
[Etiology and surgical treatment of alopecia in children].
Topics: Alopecia; Burns; Child; Cicatrix; Hair; Humans; Scalp; Transplantation, Autologous | 1977 |
Scalpel excision of basal cell carcinomas.
Topics: Adolescent; Adult; Aged; Carcinoma, Basal Cell; Cicatrix; Facial Neoplasms; Female; Follow-Up Studie | 1978 |
Free skin flap transfer.
Topics: Adult; Arteries; Burns; Cicatrix; Female; Fistula; Humans; Male; Microsurgery; Middle Aged; Osteomye | 1976 |
Scalp as a donor site.
Topics: Adult; Burns; Child; Child, Preschool; Cicatrix; Humans; Scalp; Transplantation, Autologous | 1977 |
Congenital inclusion dermoid cysts of the scalp.
Topics: Alopecia; Child; Child, Preschool; Cicatrix; Dermoid Cyst; Female; Humans; Male; Scalp; Skin Neoplas | 1992 |
A scalp lesion over an extracerebral mass: a sign of a radiation-induced meningioma.
Topics: Adult; Alopecia; Cicatrix; Female; Hemangioma; Humans; Meningeal Neoplasms; Meningioma; Neoplasms, R | 1992 |
Trapezius myocutaneous flap for reconstruction of a large scalp defect following the excision of postburn scar carcinoma (Marjolin's ulcer).
Topics: Adult; Burns; Carcinoma, Squamous Cell; Cicatrix; Female; Humans; Necrosis; Recurrence; Scalp; Skin | 1992 |
Cutaneous scar at anterior hair line in mother and child with associated frontal bone defect in child.
Topics: Abnormalities, Multiple; Adult; Cicatrix; Ectodermal Dysplasia; Female; Frontal Bone; Genes, Dominan | 1992 |
[The surgical treatment of cicatrix alopecia of the hairy scalp using tissue expansion].
Topics: Adolescent; Adult; Burns; Child; Child, Preschool; Cicatrix; Female; Humans; Male; Middle Aged; Scal | 1992 |
Hair transplantation in females.
Topics: Alopecia; Cicatrix; Female; Hair; Humans; Scalp; Time Factors; Transplantation, Autologous | 1992 |
Congenital skull and scalp defect.
Topics: Cicatrix; Humans; Infant, Newborn; Parietal Bone; Scalp | 1991 |
[Treatment of cicatricial alopecia by the method of tissue expansion].
Topics: Alopecia; Burns; Cicatrix; Female; Hair; Humans; Male; Scalp; Tissue Expansion | 1990 |
[Application of rhomboidal excision and "W" shaped suture].
Topics: Adolescent; Adult; Child; Child, Preschool; Cicatrix; Female; Head and Neck Neoplasms; Hemangioma; H | 1990 |
Total scalp, ear, and eyebrow avulsion: aesthetic adjustment of the replanted tissue.
Topics: Adult; Cicatrix; Ear Deformities, Acquired; Ear, External; Eyebrows; Face; Humans; Male; Reoperation | 1990 |
[Scalp expansion in the treatment of cicatricial alopecia].
Topics: Adolescent; Adult; Alopecia; Child; Cicatrix; Female; Humans; Male; Scalp; Tissue Expansion | 1990 |
A new method for correction of the vertical scar observed following scalp reduction for extensive alopecia.
Topics: Alopecia; Cicatrix; Humans; Scalp; Surgical Flaps | 1990 |
Reconstructive surgery of the scalp.
Topics: Adult; Alopecia; Burns; Child; Child, Preschool; Cicatrix; Female; Hair; Humans; Male; Middle Aged; | 1989 |
[Planning of a local flap of expanded scalp for repair of alopecia cicatrisata].
Topics: Adolescent; Adult; Alopecia; Burns; Child; Child, Preschool; Cicatrix; Female; Humans; Male; Middle | 1989 |
[The Brocq pseudopelade--a disease picture or disease entity].
Topics: Adolescent; Adult; Aged; Alopecia; Child; Child, Preschool; Cicatrix; Diagnosis, Differential; Femal | 1989 |
[The treatment of late damage following burns of the head, neck and face].
Topics: Burns; Cicatrix; Facial Injuries; Humans; Scalp; Surgery, Plastic; Surgical Flaps | 1989 |
[Surgical management of squamous-cell carcinomas arising in burn scar of the scalp].
Topics: Aged; Brain Neoplasms; Burns; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Cicatrix; C | 1989 |
Upper lip reconstruction: use of the free superficial temporal artery hair-bearing flap.
Topics: Adult; Burns; Cicatrix; Hair; Humans; Lip; Male; Methods; Scalp; Surgical Flaps; Temporal Arteries | 1989 |
Postirradiation extensive cicatricial scalp alopecia treated by tissue expansion.
Topics: Adult; Alopecia; Cicatrix; Female; Humans; Prostheses and Implants; Scalp; Surgery, Plastic; Tinea C | 1989 |
[Technic of tissue expansion].
Topics: Cicatrix; Humans; Poland Syndrome; Postoperative Complications; Scalp; Surgery, Plastic; Surgical Fl | 1989 |
Tissue expansion in reconstruction.
Topics: Abdominal Muscles; Adolescent; Child, Preschool; Cicatrix; Hernia, Umbilical; Humans; Male; Postoper | 1987 |
Metaplastic synovial cyst after partial excision of nevus sebaceus.
Topics: Child; Cicatrix; Female; Hamartoma; Humans; Postoperative Complications; Prostheses and Implants; Sc | 1988 |
Calvarial erosion after scalp expansion.
Topics: Alopecia; Bone Transplantation; Brain Edema; Child, Preschool; Cicatrix; Craniotomy; Hematoma, Subdu | 1987 |
Subcutaneous anterior hairline forehead rhytidectomy.
Topics: Adult; Blepharoptosis; Cicatrix; Evaluation Studies as Topic; Female; Follow-Up Studies; Forehead; H | 1988 |
Free flap donor site refinement using tissue expansion.
Topics: Adult; Back; Cicatrix; Forearm; Humans; Male; Prostheses and Implants; Scalp; Surgical Flaps; Thigh | 1988 |
The temporal island scalp flap for management of facial burn scars.
Topics: Adult; Burns; Cicatrix; Facial Injuries; Humans; Male; Scalp; Surgical Flaps | 1988 |
[Tissue expansion: histological aspects and value in the treatment of scars of the scalp].
Topics: Cicatrix; Hair Diseases; Humans; Male; Scalp; Skin; Surgery, Plastic; Surgical Flaps | 1988 |
Tissue expansion in cicatricial alopecia.
Topics: Adult; Alopecia; Cicatrix; Female; Humans; Prostheses and Implants; Scalp; Skin; Skin Physiological | 1987 |
Halo scalp ring: a cause of scarring alopecia.
Topics: Alopecia; Birth Injuries; Cicatrix; Female; Humans; Infant; Scalp | 1987 |
Massive lymphocyte-mediated apoptosis during the early stage of pseudopelade.
Topics: Alopecia; Cell Survival; Cicatrix; Epithelium; Hair; Humans; Lymphocytes; Scalp; Time Factors | 1986 |
Male baldness: immediate single-stage rotation of very long arterialized temporo-parieto-occipital flaps.
Topics: Alopecia; Cicatrix; Evaluation Studies as Topic; Humans; Male; Methods; Postoperative Complications; | 1986 |
Pseudopelade of Brocq.
Topics: Adolescent; Adult; Aged; Alopecia; Cicatrix; Diagnosis, Differential; Female; Humans; Immunoglobulin | 1986 |
[Repair of a scarring alopecia defect with a single-pedicled scalp flap].
Topics: Adolescent; Adult; Alopecia; Cicatrix; Female; Humans; Male; Scalp; Surgical Flaps | 1985 |
Halo scalp ring associated with caput succedaneum.
Topics: Adult; Alopecia; Birth Injuries; Cicatrix; Edema; Female; Humans; Infant, Newborn; Scalp | 1985 |
[Transfer by microanastomosis of a scalp flap in a case of cicatricial baldness].
Topics: Alopecia; Burns; Child, Preschool; Cicatrix; Humans; Male; Microsurgery; Scalp; Surgery, Plastic; Tr | 1974 |
Cicatricial alopecia of sarcoidosis.
Topics: Adult; Alopecia; Biopsy; Cicatrix; Female; Humans; Middle Aged; Sarcoidosis; Scalp | 1973 |
A pattern for the postauricular incision in rhytidectomy.
Topics: Cicatrix; Dermatologic Surgical Procedures; Ear, External; Face; Humans; Methods; Scalp; Surgery, Pl | 1973 |
[Lichen planus with onychatrophy and cicatricial alopecia (author's transl)].
Topics: Alopecia; Atrophy; Biopsy; Blister; Cicatrix; Female; Foot Dermatoses; Hallux; Humans; Lichen Planus | 1973 |
Hair transplantation with free scalp flaps.
Topics: Adult; Alopecia; Cicatrix; Female; Hair; Humans; Male; Methods; Scalp; Temporal Arteries; Transplant | 1974 |
Facial scar deformities and their management.
Topics: Cheek; Chin; Cicatrix; Ear Deformities, Acquired; Eyelids; Face; Facial Injuries; Female; Humans; Li | 1969 |
[Experience with free compound flap transplantation].
Topics: Adult; Aged; Burns; Carcinoma, Basal Cell; Child; Child, Preschool; Cicatrix; Facial Neoplasms; Fema | 1969 |
Cicatricial alopecia: a complication of vacuum extraction.
Topics: Alopecia; Birth Injuries; Cicatrix; Extraction, Obstetrical; Humans; Infant; Male; Scalp | 1972 |
Plastic surgery evaluation report. II.
Topics: Accidents, Traffic; Adolescent; Cicatrix; Costs and Cost Analysis; Craniocerebral Trauma; Dermabrasi | 1970 |
Localized scleroderma--en coup de sabre.
Topics: Child; Cicatrix; Eyebrows; Humans; Male; Pigmentation Disorders; Scalp; Scleroderma, Systemic | 1968 |
Congenital defect of the scalp.
Topics: Alopecia; Blindness; Child; Cicatrix; Female; Humans; Pigmentation Disorders; Scalp | 1968 |